

**THE USE OF A THYROID UPTAKE SYSTEM FOR ASSAYING INTERNAL
CONTAMINATION FOLLOWING A RADIOACTIVE DISPERSAL EVENT**

**A Thesis
Presented to
The Academic Faculty**

By

Sarah Brashear Scarboro

**In Partial Fulfillment
Of the Requirements for the Degree
Master of Science in the
School of Nuclear and Radiological Engineering and Medical Physics**

Georgia Institute of Technology

May 2008

**THE USE OF A THYROID UPTAKE SYSTEM FOR ASSAYING INTERNAL
CONTAMINATION FOLLOWING A RADIOACTIVE DISPERSAL EVENT**

Approved by:

Dr. Nolan E Hertel, Advisor
School of Nuclear and Radiological Engineering
and Medical Physics
Georgia Institute of Technology

Dr. Chris Wang
School of Nuclear and Radiological Engineering
and Medical Physics
Georgia Institute of Technology

Dr. Armin Ansari
Radiation Studies Branch
Centers for Disease Control and Prevention

Dr. Rebecca Howell
Assistant Professor, Radiation Physics
University of Texas-Houston
MD Anderson Cancer Center

Date Approved: March 28, 2008

ACKNOWLEDGEMENTS

I must give all credit for this work to God. I have learned that with Him all things are possible, and without Him, nothing. I have learned to lean on His Word and trust His love, knowing that He will also guide me through all my future endeavors.

I want to thank my thesis committee, Dr. Chris Wang, Dr. Armin Ansari, and Dr. Rebecca Howell. Your time and feedback were invaluable and I appreciate everything you have taught me. I want to acknowledge the Radiation Studies Branch of the Centers for Disease Control and Prevention for funding this research. I must also thank Mary Anne Dell from Capintec for loaning Georgia Tech a Captus 3000 Thyroid Uptake System. Without her generosity, this project could not have been completed.

I want to thank Dr. Hertel for being my advisor and mentor. I have learned a great deal from you, both inside and outside the classroom, and have truly enjoyed being one of your students. I also want to thank the rest of Team Hertel for all your contributions to this project. I especially want to thank Eric Burgett and Rebecca Howell. Eric for patiently teaching me MCNP and being my constant support desk, and Rebecca for facilitating all the time I have spent at Emory and for inspiring me to pursue medical physics.

I want to thank my family – especially Mom, Dad, and Laura. You have given more of yourselves than I could ever ask for, and I am who I am because of you. And finally, I want to thank my husband, PJ, for everything you do and everything you are. I cherish your love and support. Thank you for encouraging me through this long process, for sitting with me during late nights of data collection, for discussing this project with me ad nauseum, for reading countless drafts, and for always loving me. I couldn't have done this without you.

TABLE OF CONTENTS

| | |
|---|------|
| ACKNOWLEDGEMENTS | iii |
| LIST OF TABLES | vi |
| LIST OF FIGURES | x |
| SUMMARY | xiii |
| CHAPTER | |
| 1 INTRODUCTION | 1 |
| 2 LITERATURE REVIEW | 3 |
| 3 METHODOLOGY | 6 |
| 3.1 Capintec Captus 3000 Thyroid Uptake System Overview | 6 |
| 3.2 Measurements using PMMA Slab Phantom | 8 |
| 3.3 Detector Model and Validation | 10 |
| 3.4 Development of Emergency Screening Protocol | 11 |
| 3.5 Considerations of Decision Levels and Minimum Detectable Activity | 13 |
| 3.6 Considerations of the Minimum Detectable Dose | 14 |
| 4 COMPUTATIONAL MODELS | 16 |
| 4.1 Thyroid Uptake Collimator Model | 16 |
| 4.2 Slab Phantom Model | 18 |
| 4.3 MIRD Phantom Models | 22 |
| 5 BIOKINETIC MODELING | 27 |
| 6 RESULTS | 35 |
| 6.1 Model Validation | 35 |
| 6.2 MIRD Phantom Results | 44 |

| | |
|--|-----|
| 6.3 Consideration of Background Spectra | 50 |
| 6.4 Decision Levels | 52 |
| 6.5 Personal Contamination Screening Threshold Determination | 54 |
| 7 CONCLUSIONS | 71 |
| 8 FUTURE WORK | 73 |
| APPENDIX A: Thyroid Uptake Collimator and Slab Phantom MCNP Input File | 74 |
| APPENDIX B: Slab Phantom Spectral Data | 77 |
| APPENDIX C: Condensed MIRD Phantom MCNP Input File | 87 |
| APPENDIX D: MIRD Phantom Count Rate Results | 97 |
| REFERENCES | 113 |

LIST OF TABLES

| | | |
|-------------|---|----|
| Table 3.2.1 | Selected isotopes and photon energies for benchmark measurements and detector validation | 10 |
| Table 3.4.1 | Selected isotopes and photon energies for use with anthropomorphic phantoms | 12 |
| Table 3.4.2 | Anthropomorphic Phantom Simulations Completed | 13 |
| Table 4.1.1 | Material composition of steel used in Thyroid Uptake Collimator model by atom fraction | 17 |
| Table 4.1.2 | Material compositions of materials used in Thyroid Uptake Collimator model by atom fraction | 17 |
| Table 4.2.1 | Material compositions of PMMA and Virtual Water by atom fraction | 18 |
| Table 4.2.2 | Total branching ratio for each isotope used in slab phantom calculations | 19 |
| Table 4.3.1 | Characteristics of human phantoms used in MCNP simulations | 23 |
| Table 4.3.2 | Organs where unit sources were distributed in MCNP model | 25 |
| Table 5.1 | Default lung absorption type for each isotope | 28 |
| Table 5.2 | Body Compartments identified by DCAL for each selected isotope, bolded items specific to that isotope | 30 |
| Table 6.1.1 | Capintec default ROI values used in measured and calculated spectra | 39 |
| Table 6.1.2 | Scaling factor for isotopes used in benchmark measurements and phantom calculations | 43 |
| Table 6.2.1 | Count rate per Bq calculated for the Male phantom contaminated with Cs-137 | 45 |
| Table 6.4.1 | Decision Levels for one minute counting times for the thyroid uptake collimator | 53 |

| | | |
|--------------|---|----|
| Table 6.4.2 | Count Rate per CDL for optimal detector position on male phantom, 3 days following initial intake | 54 |
| Table 6.5.1 | Dose coefficients for inhalation for one CDL (25 rem) | 55 |
| Table 6.5.2 | Count Rate per CDL for the Male phantom contaminated with Cs-137 | 55 |
| Table 6.5.3 | Count Rate per CDL for the Female phantom contaminated with Cs-137 | 56 |
| Table 6.5.4 | Count Rate per CDL for the Adipose Male phantom contaminated with Cs-137 | 56 |
| Table 6.5.5 | Count Rate per CDL for Adipose Female phantom contaminated with Cs-137 | 57 |
| Table 6.5.6 | Count Rate per CDL for Post-Menopausal Adipose Female phantom contaminated with Cs-137 | 57 |
| Table 6.5.7 | Count Rate per CDL for the Child phantom contaminated with Cs-137 | 58 |
| Table 6.5.8 | Count Rate per CDL for the Male phantom contaminated with Co-60 | 58 |
| Table 6.5.9 | Count Rate per CDL for the Female phantom contaminated with Co-60 | 59 |
| Table 6.5.10 | Count Rate per CDL for the Adipose Male phantom contaminated with Co-60 | 59 |
| Table 6.5.11 | Count Rate per CDL for the Adipose Female phantom contaminated with Co-60 | 60 |
| Table 6.5.12 | Count Rate per CDL for the Post-Menopausal Adipose Female phantom contaminated with Co-60 | 60 |
| Table 6.5.13 | Count Rate per CDL for the Child phantom contaminated with Co-60 | 61 |
| Table 6.5.14 | Count Rate per CDL for each Male phantom contaminated with Am-241 | 61 |
| Table 6.5.15 | Count Rate per CDL for the Female phantom contaminated with Am-241 | 62 |

| | | |
|--------------|--|----|
| Table 6.5.16 | Count Rate per CDL for the Adipose Male phantom contaminated with Am-241 | 62 |
| Table 6.5.17 | Count Rate per CDL for the Adipose Female phantom contaminated with Am-241 | 63 |
| Table 6.5.18 | Count Rate per CDL for the Post-Menopausal Adipose Female phantom contaminated with Am-241 | 63 |
| Table 6.5.19 | Count Rate per CDL for the Child phantom contaminated with Am-241 | 64 |
| Table 6.5.20 | Count Rate per CDL for the Male phantom contaminated with I-131 | 64 |
| Table 6.5.21 | Count Rate per CDL for the Female phantom contaminated with I-131 | 65 |
| Table 6.5.22 | Count Rate per CDL for the Adipose Male phantom contaminated with I-131 | 65 |
| Table 6.5.23 | Count Rate per CDL for the Adipose Female phantom contaminated with I-131 | 66 |
| Table 6.5.24 | Count Rate per CDL for the Post-Menopausal Adipose Female phantom contaminated with I-131 | 66 |
| Table 6.5.25 | Count Rate per CDL for the Child phantom contaminated with I-131 | 67 |
| Table 6.5.26 | Count Rate per CDL for the Male phantom contaminated with Ir-192 | 67 |
| Table 6.5.27 | Count Rate per CDL for the Female phantom contaminated with Ir-192 | 68 |
| Table 6.5.28 | Count Rate per CDL for the Adipose Male phantom contaminated with Ir-192 | 68 |
| Table 6.5.29 | Count Rate per CDL for the Adipose Female phantom contaminated with Ir-192 | 69 |
| Table 6.5.30 | Count Rate per CDL for the Post-Menopausal Adipose Female phantom contaminated with Ir-192 | 69 |

| | | |
|--------------|---|----|
| Table 6.5.31 | Count Rate per CDL for the Child phantom contaminated with Ir-192 | 70 |
|--------------|---|----|

LIST OF FIGURES

| | | |
|--------------|---|----|
| Figure 3.1.1 | Capintec Captus 3000 Thyroid Uptake System with thyroid uptake collimator | 7 |
| Figure 3.2.1 | PMMA Slab Phantom: 10 cm virtual water, source holder, and 60 mm PMMA | 8 |
| Figure 3.2.2 | Position of source relative to detector | 9 |
| Figure 4.1.1 | (A) MCNP model of thyroid uptake collimator as displayed in VisEd; (B)Captus 3000 thyroid uptake collimator | 17 |
| Figure 4.2.1 | Cross-sectional VisEd representation of the slab phantom and thyroid uptake probe with source positioning | 18 |
| Figure 4.2.2 | VisEd representation of the emissions from the source and collisions in surrounding materials | 20 |
| Figure 4.2.3 | Comparison of Measured Spectrum with Smoothed and Unsmoothed Calculated Spectra | 21 |
| Figure 4.2.4 | Detector resolution verse energy for the isotopes chosen to calculate the GEB parameters | 22 |
| Figure 4.3.1 | Thyroid uptake collimator positions on the Male anthropomorphic phantom | 24 |
| Figure 5.1 | Comparison of Total Fraction Retained for each selected isotope | 29 |
| Figure 5.2 | Retention of Cs-137 in the lungs and body tissue and total fraction retained over first 30 days following intake | 31 |
| Figure 5.3 | Retention of Co-60 in the lungs, body tissue, and liver and total fraction retained over first 30 days following intake | 31 |
| Figure 5.4 | Retention of I-131 in the lungs, body tissue, and thyroid and total fraction retained over first 30 days following intake | 32 |
| Figure 5.5 | Retention of Ir-192 in the lungs, body tissue, liver, kidneys, and spleen and total fraction retained over first 30 days following intake | 32 |

| | | |
|---------------|---|----|
| Figure 5.6 | Retention of Am-241 in the lungs, body tissue, liver, kidneys, and bone (including red bone marrow) and total fraction retained over first 30 days following intake | 33 |
| Figure 5.7 | Retention of Sr/Y-90 in the lungs, body tissue, and bone and total fraction retained over first 30 days following intake | 33 |
| Figure 6.1.1 | Measured and calculated spectra for Am-241 with 60 mm PMMA | 36 |
| Figure 6.1.2 | Measured and calculated spectra for Ba-133 with 60 mm PMMA | 36 |
| Figure 6.1.3 | Measured and calculated spectra for Cs-137 with 60 mm PMMA | 37 |
| Figure 6.1.4 | Measured and calculated spectra for Co-60 with 60 mm PMMA | 37 |
| Figure 6.1.5 | Measured and calculated spectra for Mn-54 with 60 mm PMMA | 38 |
| Figure 6.1.6 | Measured and calculated spectra for Na-22 with 60 mm PMMA | 38 |
| Figure 6.1.7 | Ratio of MCNP results to measured data for the 662 keV photopeak from Cs-137, with mean of 1.05 | 40 |
| Figure 6.1.8 | Ratio of MCNP results to measured data for the sum of the 1.17 and 1.33 MeV photopeaks from Co-60, with mean of 1.09 | 40 |
| Figure 6.1.9 | Ratio of MCNP results to measured data for the sum of the 0.511 and 1.27 MeV photopeaks from Na-22, with mean of 1.05 | 41 |
| Figure 6.1.10 | Ratio of MCNP results to measured data for the 835 keV photopeak from Mn-54, with mean of 1.07 | 41 |
| Figure 6.1.11 | Ratio of MCNP results to measured data for the sum of the 31, 80, and 356 keV photopeaks from Ba-133, with mean of 0.93 | 42 |
| Figure 6.1.12 | Ratio of MCNP results to measured data for the 59.5 keV photopeak from Am-241, with mean of 1.31 | 42 |
| Figure 6.2.1 | Comparison of count rate per phantom type for Cs-137, with detector positions on the neck | 46 |
| Figure 6.2.2 | Count Rate per Bq of intake of I-131 for the neck position | 47 |
| Figure 6.2.3 | Comparison of detector position and phantom type for Co-60, 3 days after intake | 48 |

| | | |
|--------------|---|----|
| Figure 6.2.4 | Count rate as a function of time for each phantom type contaminated with Ir-192 | 49 |
| Figure 6.3.1 | Background spectrum collected at Georgia Tech laboratory | 52 |

SUMMARY

This work investigated the use of a common medical device, a thyroid uptake system or thyroid probe, in assessing internal contamination in individuals. In the event of a terrorist act involving a radiological agent, there will be a need to effectively and rapidly screen a large number of people for internal contamination. Using the methodology outlined in this work, those needing further medical assistance can be identified and separated from uncontaminated or very lightly contaminated people. Additionally, this information could be stored in a registry to track population contamination.

A series of measurements and models were used to estimate the response of the thyroid probe to radioactive isotopes in various human phantoms. First, benchmark measurements were made using a polymethyl methacrylate (PMMA) slab phantom and a variety of gamma-ray emitting isotopes. The experimental setup was recreated in a computational model using the Los Alamos Monte Carlo N-Particle Transport Code, MCNP5. [45] The thyroid uptake collimator was also modeled using this code and simulations were completed for each laboratory measurement. A comparison of these results validated the computational model of the thyroid uptake collimator and provided any required normalization factors.

Six anthropomorphic phantoms of varying age and body type were then used in conjunction with the thyroid uptake collimator. These phantoms are based on the Medical Internal Radiation Dose (MIRD) phantoms [7], originally developed at Oak Ridge National Laboratory. Uniformly distributed isotopic sources were placed in all the affected organs according to biokinetic models generated by the Dose and Risk Calculation Software (DCAL). [9]

The results of this work demonstrate that the thyroid uptake probe is a viable tool for assessing internal contamination due to Cs-137, Co-60, I-131, and Ir-192, even at relatively high levels of background. However, this work found that a collimated thyroid uptake probe could not be used to assess individuals internally contaminated with Am-241. The Decision Level (DL) count rate for Am-241 exceeds the expected count rate due to an intake of one Clinical Decision Level (1 CDL is approximately 25 rem) by several orders of magnitude. The most effective location of the thyroid probe for Co-60 and Ir-192 is on the back over the right lung. Two of the isotopes investigated, I-131 and Cs-137, have a recommended lung absorption type of fast. This results in a higher uptake to various tissues, and a smaller fraction of the isotope remaining in the lungs. Thus, for these isotopes, positioning the detector against the neck produces the highest count rate. In general, an increase in body mass index (BMI) adversely affects the count rate per becquerel of activity intake.

CHAPTER 1

INTRODUCTION

After the events of September 11, 2001, the threat of a terrorist act involving chemical, biological, or radiological agents has demanded the attention of government officials and public health agencies. While the ultimate consequence of such an event is difficult to predict, the psychological and economic impact on the United States could be devastating.

With regard to radiological terrorism, weapons are no longer limited to atomic bombs or nuclear devices, such as those used at Hiroshima and Nagasaki. The dispersal of radioactive material into the environment – with or without an associated explosion – is now considered a principal threat. [6] A Radiological Dispersal Device (RDD) is a particular concern due to the widespread use of radioactive materials in foreign and domestic industries. [2]

Radioactive materials are used in the petroleum industry, in health care for diagnostic and therapeutic applications, and in electric power generation. The applications of these materials are as diverse as the isotopes themselves. A work conducted at Sandia National Laboratories examined radioactive materials at facilities licensed by the Nuclear Regulatory Commission (NRC) and controlled and managed by the Department of Energy (DOE). The purpose of the analysis was to determine the relative availability of several nuclear materials and to identify those of greatest concern, or those thought to be most likely used in a RDD. The materials identified by Sandia National Laboratories include Am-241, Cs-137, Co-60, and Ir-192. [36]

One principal health threat resulting from a RDD is internal contamination due to inhalation. Radioactive dust or smoke resulting from an associated explosion or particulate

radioactive materials dispersed into the air could be inhaled and subsequently spread throughout the individual's body. Depending on the isotope, a significant fraction of the intake could remain in the lungs up to several days. This is the optimal window of time to assay internal contamination and make determinations of the need for further medical care to ameliorate the health impact.

Recent publications have examined the feasibility of using a thyroid uptake system to monitor personal internal contamination due to inhalation. [24, 1] As a common nuclear medicine apparatus, the thyroid uptake system is readily available in hospital Nuclear Medicine departments, and is a functional tool for use in an emergency scenario. The ultimate choice in assaying internal contamination, particularly for trace amounts of internal contamination, is a whole body counter (WBC) such as those found at nuclear power facilities. WBCs are highly sensitive, and this level of sensitivity is more than what is needed for emergency triage. In addition, these devices are rarely found in major cities, and in the absence of WBCs, other common radiation detectors have been considered for the rapid and effective triage of potentially contaminated victims.

This work attempts to determine count rates corresponding to various Clinical Decision Levels (CDLs) using Monte Carlo simulation techniques for the Captus 3000 Thyroid Uptake System. For the purpose of this work, one CDL is defined as the intake that results in 25 rem of committed effective dose. [34] This unit was recommended by the Centers for Disease Control and Prevention to be used to quantify count rate thresholds for emergency procedure protocols. Six Medical Internal Radiation Dose (MIRD) phantom types were also examined to estimate the effects of body type and body mass index on the count rates.

CHAPTER 2

LITERATURE REVIEW

In addition to many individuals and organizations, the Centers for Disease Control and Prevention (CDC) and the Nuclear Regulatory Commission (NRC) have published several recent documents concerning emergency medical response to a RDD. These documents include feasibility reports, guidelines, and evaluations of current levels of preparedness. One such document, published by the Belgian Nuclear Research Center, discussed the direct and indirect effects of a radiological attack on a populous area. The direct and immediate effects could include death, injury, contamination, and societal chaos. Delayed effects regarding contamination of food or water supplies and the economic ramifications of such a disaster also present a unique problem. [39] The principal concern is a need for preparedness – both in emergency response and in addressing the long-term effects of such an event.

Several studies have addressed the risk and potential dose to healthcare providers treating contaminated victims following a radiological terrorist event. According to surveys conducted among medical personnel, there exists a significant concern about the risk associated with treating a radioactively-contaminated patient. Despite these concerns, medical guidelines state that the treatment of life-threatening injuries and medical stabilization of a patient should not be delayed for decontamination efforts. [38]

The standard for assessing contamination (both internal and external) in radiation occupations is a Whole Body Counter (WBC). A WBC is generally constructed of an array of NaI(Tl) detectors surrounded by some back-ground reducing material. WBCs can be orientated such that the individual walks into or through the detectors. Numerous studies have been

conducted on the efficiency and sensitivity of WBCs for applications both in emergency response and occupational monitoring. One emergency scenario in which a WBC was employed was following the Cs-137 accident in Goiania, Brazil. This system was constructed in the field using a 20 cm NaI(Tl) mounted approximately 2 m off the ground in a small room. This detector was used to successfully assay over 300 people following the accident. [33]

Internal contamination is a primary cause of committed effective dose to the victim following an RDD. The development of instruments and protocols to estimate internal contamination is the topic of recent studies conducted at the Georgia Institute of Technology. These studies have examined a variety of instruments for both their feasibility and efficiency in detecting internal contamination due to inhalation of radioactive material.

A study conducted by S. Cohen and Associates [1] evaluated the feasibility of using various hospital radiation detectors to assess internal contamination from inhaled radionuclides. The detection systems included in this study are commonly found in hospitals, especially those performing nuclear medicine studies. Based on simulations using an acrylic slab phantom and a water filled phantom, the SC&A study concluded that the gamma camera, thyroid uptake system, and waste monitor are each capable of detecting low levels of radiation and can potentially be used in the aftermath of a terrorist event.

With regard to the thyroid uptake system, the SC&A investigation looked specifically at the Atomlab 950 Thyroid Uptake System. The Atomlab 950 consists of a 2" by 2" NaI crystal with a lead collimator extending approximately six inches from the detector face. This is the same thyroid uptake system that was the primary focus of a thesis completed by Ryan Lorio. [24] The Lorio work also sought to examine the feasibility of using a thyroid uptake system for

estimating dose to individuals following a terrorist event; and furthermore, it sought to develop a validated Monte Carlo model of this probe to estimate uptake to the lungs.

While the work completed by Lorio proved that the use of this system is feasible following an RDD, the models considered did not include the movement of an isotope through the body, or the fraction remaining in various organs over time. To further refine the conclusions, this work will include biokinetic modeling while determining the detector response for internal contamination from various phantom types.

CHAPTER 3

METHODOLOGY

3.1 Captus 3000 Thyroid Uptake System Overview

The Captus 3000 Thyroid Uptake System is manufactured by Capintec, Inc, and is a fully automated, PC-based system which is typically used to perform thyroid uptake tests, bioassay tests, and other lab tests. The system includes two 2” Sodium-Iodide (NaI) detectors mounted on articulating spring arms, a 1024-channel multi-channel analyzer (MCA), and several modules for calibration, measurements, and reporting. Both detectors are collimated with a lead-antimony composite material. The thyroid uptake collimator is longer, extending approximately 16 centimeters from the detector face. The bioassay collimator is shorter, extending only approximately six centimeters from the detector. All Captus 3000 thyroid uptake systems include the thyroid uptake collimator while the bioassay collimator is an optional feature. The focus of this work is on the standard thyroid uptake collimator. The system stores patient information and demographics as well as all collected spectral or counting data. These features are very useful for generating detailed thyroid uptake reports and staff bioassays; reports can be saved and printed as individual reports or as a cumulative history. The Captus 3000 system is shown in Figure 3.1.1.



Figure 3.1.1 Capintec Captus 3000 Thyroid Uptake System with thyroid uptake collimator.

As specified in the user's manual, the Captus 3000 must be auto-calibrated using two calibration sources (Cs-137 and Eu-152, included with system) daily before measurements are collected or tests are performed. In addition, the chi-squared calibration test must be performed before initial use, and then quarterly. All calibration tests were performed successfully at Georgia Tech prior to data collection.

The manual MCA interface was used for all measurements in this work. The MCA calibration is set to 2 keV per channel, allowing it to bin pulse-height data for gamma energies up to 2 MeV. The MCA system is equipped to automatically identify the regions of interest (ROI) based on an isotope selection. It is unrealistic to expect emergency operators to manually adjust the ROIs in the field. Therefore, the system default ROIs set on photopeaks were used in both the data collection and the model validation. Each MCA spectrum report was exported as a spreadsheet and saved, allowing background correction and data analysis.

3.2 Measurements using PMMA Slab Phantom

The thyroid uptake collimator was used to make a series of benchmark measurements with various isotopes. The measurements were made using a slab phantom composed of polymethyl methacrylate (PMMA) and virtual water. PMMA was chosen for its attenuation properties, which are similar to those of human tissue. Virtual WaterTM (MED-CAL, Inc., Verone, WI) [43] was used as backscatter material, placed furthest from the detector face and behind the source. The thickness of the backscatter material was 10-cm for all measurements. A 6-mm thick PMMA ‘source holder’ was placed flush against the virtual water. A cylindrical hole in the center of the source holder contained the source, preventing the source from shifting during measurements. Slabs of PMMA were placed in front of the source holder to increase or decrease the thickness of attenuating material between the source and the detector. The experimental set-up used for measurements with the PMMA slab phantom is shown in Figure 3.2.1.




Figure 3.2.1 PMMA Slab Phantom: 10 cm virtual water, source holder, and 60 mm PMMA

The source was centered on the opening of the collimator, and taped in place to prevent movement during a set of measurements. The source position relative to the detector face is shown in Figure 3.2.2. The position of the source holder relative to the PMMA, Virtual Water, and detector is shown above in Figure 3.2.1.




Figure 3.2.2 Position of source relative to detector.

Some of the isotopes of greatest concern for use in a RDD are Co-60, Cs-137, and Am-241. These isotopes, along with three others, were used to encompass a broad range of gamma-ray energies. This selection was based largely on the availability of the sources. The isotopes that were used in detector characterization and their associated photon energies and intensities (Rad Toolbox) [8] are shown in Table 3.2.1

Table 3.2.1 Selected isotopes and photon energies for benchmark measurements and detector validation

| Isotope | Photon Energy, MeV | Photon Emission Intensity |
|----------------|---|--|
| Am-241 | 0.059, 0.026, 0.021, 0.0179, 0.0177, 0.017, 0.0168, 0.0139, 0.0137 | 0.357, 0.024, 0.045, 0.019, 0.188, 0.022, 0.058, 0.219, 0.024 |
| Ba-133 | 0.384, 0.356, 0.303, 0.276, 0.081, 0.035, 0.031, 0.030 | 0.089, 0.622, 0.184, 0.071, 0.338, 0.122, 0.631, 0.341 |
| Cs-137 | 0.662 | 0.853 |
| Co-60 | 1.332, 1.173 | 0.999, 0.999 |
| Mn-54 | 0.8348 | 0.999 |
| Na-22 | 1.275, 0.511 | 0.999, 1.798 |

For each measured isotope, a spectrum was collected for PMMA thicknesses ranging from 0-mm to 108-mm in six millimeter increments. Counting time was determined based on counting in the ROI. A minimum of 10,000 counts before background subtraction (corresponding to 1% counting error under the peak) was specified for each thickness.

Background corrections were applied to the spectra outside of the Capintec software. Before each set of measurements, a ten minute background spectrum was acquired and then subtracted from each of the measured spectra. No other corrections were made to the raw data.

3.3 Detector Model and Validation

The benchmark measurements were used to validate a computational model of the thyroid uptake collimator and detector. The purpose of this model was to accurately represent the detector so that simulations on contaminated ‘people’ could be performed using computer models. Details concerning the detector and slab phantom computational model are discussed in Chapter 4.

The detector response was calculated for the same PMMA thicknesses as the benchmark measurements. Also, the response to each isotope was calculated separately to ensure that the detector model was validated over a range of gamma-ray energies.

The measured pulse-height spectra were individually integrated over the entire spectrum, and over each photopeak. These values were compared to the corresponding calculated detector response for each isotope and each thickness of PMMA. Validation of the model requires that the ratio of calculated to measured count rate is constant over the range of attenuation thicknesses.

3.4 Development of Emergency Screening Protocols

The validated detector model was used to simulate the detector response on an internally contaminated human. Medical Internal Radiation Dose (MIRD) male and female phantoms based on the reference man were used. These phantoms were originally developed at Oak Ridge National Laboratory. [7] The MCNP models of the reference male and female phantoms were developed at the Pacific Northwest National Laboratory in the late 1980's. These phantoms have been used and further refined at the Georgia Institute of Technology in dose conversion coefficient studies in recent years. One of the major works at Georgia Tech on these phantoms was the addition of adipose tissue to the reference male and female phantoms to create three additional phantoms: Adipose Male, Adipose Female, and Post-Menopausal Adipose Female. [37] Other modifications made to the phantoms include the addition of an esophagus and a walled colon. A child phantom was created using the Bodybuilder Phantom [44] and included in the simulations. In total, six anthropomorphic phantoms were used: Male, Female, Adipose Male, Adipose Female, Post-Menopausal Adipose Female, and a 10-year-old Child.

Five sources were chosen based on those noted by the Nuclear Regulatory Commission as being “isotopes of greatest concern.” [6] These sources (Cs-137, Co-60, Am-241, I-131, and Ir-192) have distributions in various organs in the human body as a function of time when inhaled. To fully characterize the isotopes behavior in the body, the isotopes were distributed throughout the organs based on biokinetic models for inhalation. Details concerning biokinetic modeling are further described in Chapter 5. Table 3.4.1 shows the energy and intensity for the five isotopes of concern used in conjunction with the anthropomorphic phantoms.

Table 3.4.1 Selected isotopes and photon energies for use with anthropomorphic phantoms

| Isotope | Photon Energy, MeV | Photon Emission Intensity |
|----------------|---|--|
| Am-241 | 0.059, 0.026, 0.021, 0.0179, 0.0177, 0.017, 0.0168, 0.0139, 0.0137 | 0.357, 0.024, 0.045, 0.019, 0.188, 0.022, 0.058, 0.219, 0.024 |
| Cs-137 | 0.662 | 0.853 |
| Co-60 | 1.332, 1.173 | 0.999, 0.999 |
| I-131 | 0.364, 0.637, 0.284, 0.723 | 0.812, 0.727, 0.606, 0.018 |
| Ir-192 | 0.317, 0.468, 0.308, 0.296, 0.604, 0.612, 0.589, 0.485 | 0.828, 0.478, 0.297, 0.290, 0.0818, 0.0533, 0.0452, 0.0316 |

The detector was placed in four locations on the male phantom: front right lung, the back right lung, the front of the neck, and the outer left thigh. The other four adult phantoms have significantly more breast tissue than the male phantom. Thus, the front right lung position was excluded for these phantom types (due to the attenuation caused by breast tissue).

Computer simulations were completed for each combination of phantom and isotope, yielding 30 combinations. The completed simulations are shown in Table 3.4.2.

Table 3.4.2 Anthropomorphic Phantom Simulations Completed

| Phantom Type | Isotope |
|--------------------------------|----------------|
| Male | Cs-137 |
| Male | Co-60 |
| Male | Am-241 |
| Male | I-131 |
| Male | Ir-192 |
| Female | Cs-137 |
| Female | Co-60 |
| Female | Am-241 |
| Female | I-131 |
| Female | Ir-192 |
| Adipose Male | Cs-137 |
| Adipose Male | Co-60 |
| Adipose Male | Am-241 |
| Adipose Male | I-131 |
| Adipose Male | Ir-192 |
| Adipose Female | Cs-137 |
| Adipose Female | Co-60 |
| Adipose Female | Am-241 |
| Adipose Female | I-131 |
| Adipose Female | Ir-192 |
| Post Menopausal Adipose Female | Cs-137 |
| Post Menopausal Adipose Female | Co-60 |
| Post Menopausal Adipose Female | Am-241 |
| Post Menopausal Adipose Female | I-131 |
| Post Menopausal Adipose Female | Ir-192 |
| Child | Cs-137 |
| Child | Co-60 |
| Child | Am-241 |
| Child | I-131 |
| Child | Ir-192 |

3.5 Considerations of the Decision Level and Minimum Detectable Activity

The minimum detectable activity (MDA) for each isotope was considered to establish count rate thresholds for the thyroid uptake collimator. First, a decision level (DL) is defined as the net count rate indicating the presence of radioactive material with some predetermined confidence level. A general expression for this limit is shown in Equation 3.5.1. [40]

$$\text{DL (counts per minute)} = 1.645 \sqrt{R_b \left(\frac{1}{t_b} + \frac{1}{t_g} \right)} \quad [\text{Eqn 3.5.1}]$$

In this expression,

R_b = background count rate

t_b = background counting time

t_g = gross counting time

The MDA is a value of activity that would result in a count rate less than the DL a certain fraction of the time. This occurrence is a false negative, because there is actual activity present, but the system does not identify it based on the set decision level. It is generally accepted to specify a 5% false negative rate. An expression for the MDA is shown in Equation 3.5.2. [40]

$$\text{MDA in } \mu\text{Ci} = \frac{3 + 3.29 \sqrt{R_b t_g \left(1 + \frac{t_g}{t_b} \right)}}{K t_g} \quad [\text{Eqn 3.5.2}]$$

In this expression,

K = counting yield, or counting efficiency.

The MDA should not be compared to the measured count rate as it is a performance indicator for the counting system. Instead, the determined DL should be compared to the count rate as an indicator for the presence of activity in the sample. For this work, the calculated count rates were compared to the DL count rate for various counting times and background levels. These results are described in Chapter 6, Section 3.

3.6 Considerations of the Minimum Detectable Dose

The minimum detectable dose (MDD) is a valuable quantity for bioassay applications. The MDD is directly proportional to the MDA and takes into account the biological half-life and

retention fraction of a particular isotope. An expression for the MDD is shown in Equation 3.6.1. [40]

$$\text{MDD} = \frac{\text{MDA}}{Y_{\text{RC}} V_{\text{bio}} \text{IRF}_u(\Delta t)} \times h_{\text{E},50} \quad [\text{Eqn 3.6.1}]$$

In this expression,

Y_{RC} = radiochemical yield of the isotope of interest

V_{bio} = biological variability in excretion rates and volumes

IRF_n = intake retention fraction, or the fraction of the intake that remains in any
bioassay compartment

Δt = time between intake and the bioassay measurement

$h_{\text{E},50}$ = 50-year committed effective dose per unit intake (ICRP 1994)

MDD values are not directly relevant to the intent of this work, therefore they were not calculated.


CHAPTER 4

COMPUTATIONAL MODELS

Computational models were developed to accurately represent the response of various detection systems to internal contamination in humans. The Los Alamos Code, MCNP Version 5 [45], was used to simulate the photon transport essential to replicating the response of the thyroid uptake collimator and detector. The results of these simulations allow validation of the methodology by comparison with experimental measurements. These computational models can also be used for comparison to other studies involving thyroid uptake counters. A summary of the computational models used in this research is included below, including the use of various human phantoms internally contaminated with the five selected isotopes.

4.1 Thyroid Uptake Collimator Model

The thyroid uptake collimator was modeled using the Los Alamos N-Particle Transport Code MCNP5. [45] Specifications from Capintec were used to model the critical components of the detector and collimator. The NaI detector crystal was manufactured by Saint Gobain [35] and is surrounded by 0.508 mm of Aluminum. The photomultiplier tube is mounted directly against the back of the crystal, and was represented by an enclosed cylindrical vacuum in the model. A detector side shield (3.175 mm thick lead) wraps around the detector and connects to the collimator. The 2" x 2" Ø NaI crystal and photomultiplier tube are housed in a lead and antimony collimator, which extends approximately 16 cm from the face of the crystal. The entire collimator is enclosed in an outer steel layer that is painted. The layer of paint was not included in the model. A cross-sectional view generated with the VisEd program [46] of the model and a side view of the actual collimator is shown in Figure 4.1.1.



**Figure 4.1.1 (A) MCNP model of thyroid uptake collimator as displayed in VisEd;
(B) Captus 3000 thyroid uptake collimator**

The material compositions of the various components were either obtained from the Capintec drawings, or were selected based on industry standards. The exact material compositions used in the thyroid uptake collimator model are shown in Table 4.1.1 and Table 4.1.2.

Table 4.1.1 Material composition of steel used in Thyroid Uptake Collimator model by atom fraction

| | Density | Carbon | Oxygen | Phosphorus | Manganese | Iron |
|-------------------|-----------|----------|----------|------------|-----------|--------|
| AISI 1000 [26] | 7.82 g/cc | 0.002786 | 8.687E-5 | 7.1946E-5 | 0.003549 | 0.9935 |

Table 4.1.2 Material compositions of materials used in Thyroid Uptake Collimator model by atom fraction

| | Density | Aluminum | Copper | Zinc | Antimony | Lead |
|-----------------|-----------|----------|--------|------|----------|------|
| Brass | 8.4 g/cc | | 0.65 | 0.35 | | |
| Antimonial Lead | 11.4 g/cc | | | | 0.04 | 0.96 |
| Lead | 11.4 g/cc | | | | | 1 |
| Aluminum | 2.7 g/cc | 1 | | | | |

4.2 Slab Phantom Model

The slab phantom was modeled in MCNP5 for the purpose of simulating the benchmark measurements made in the laboratory. Variations of the slab phantom were created to represent each thickness of PMMA used in laboratory measurements. The compositions of the PMMA and Virtual Water are shown in Table 4.2.1.

Table 4.2.1 Material compositions of PMMA and Virtual Water by weight percent

| | Density | Hydrogen | Carbon | Nitrogen | Oxygen | Chlorine | Calcium |
|--------------------|-----------|----------|--------|----------|--------|----------|---------|
| PMMA [24] | 1.19 g/cc | 0.5333 | 0.3333 | | 0.1333 | | |
| Virtual Water [43] | 1.03 g/cc | 0.08056 | 0.6733 | 0.02149 | 0.2000 | 0.001406 | 0.02320 |

Each source was modeled and placed at the same position in the PMMA source holder. The single isotope sources were fully encapsulated with activities ranging from 1.813×10^5 Bq to 2.775×10^5 Bq. Each source was approximately 2.3-cm in length and 0.4-cm in diameter. Figure 4.2.1 illustrates the source position relative to the collimator in the computational model.




Figure 4.2.1 Cross-sectional VisEd representation of the slab phantom and thyroid uptake probe with source positioning.

A pulse height tally (MCNP F8 tally) was performed over the NaI crystal volume for the photons (shown in Table 3.2.1) emitted by the sources. MCNP tallies are normalized by the code to an emission of one source particle. The tally output must then be multiplied by the exact activity of the laboratory source and branching ratios for a direct comparison. For four of the isotopes used in the detector validation (Co-60, Am-241, Ba-133, Na-22), multiple gamma-rays are emitted for every particle disintegration. In this case, the sum of the branching ratios (or the total number of photons emitted per decay) is used. The branching ratios used are shown in Table 4.2.2.

Table 4.2.2 Total branching ratio for each isotope used in slab phantom calculations

| Isotope | Branching Ratio |
|---------|-----------------|
| Am-241 | 0.9592 |
| Ba-133 | 2.3966 |
| Cs-137 | 0.8528 |
| Co-60 | 1.9988 |
| Mn-54 | 0.9997 |
| Na-22 | 2.7974 |

A VisEd generated simulation of the emissions from the source and collisions in the surrounding materials as sampled in MCNP is shown in Figure 4.2.2.




Figure 4.2.2 VisEd representation of the emissions from the source and collisions in surrounding materials

A Gaussian Energy Broadening (GEB) smoothing function available as an option in MCNP was used to simulate the detector resolution. The GEB function is intended to provide a simple analytical function that represents the full width at half maximum of the physical detector to broaden the MCNP computed pulse-height spectrum to simulate the energy resolution of the detector. In the raw MCNP tally, all photoelectric interactions lead to a single energy electron rather than a resolution broadened photopeak. To illustrate the effect of the GEB smoothing function, a comparison of the raw MCNP tally, a GEB smoothed MCNP tally, and a measured spectrum for Cs-137 are shown in Figure 4.2.3.




Figure 4.2.3 Comparison of Measured Spectrum with Smoothed and Unsmoothed Calculated Spectra

The parameters required for the GEB function (*a*, *b*, and *c*) were calculated based on the measured detector response for Co-60 (1.17 MeV and 1.33 MeV) and Na-22 (0.511 MeV). The expression used to determine these three parameters is shown in Eqn 4.2.1

$$\text{FWHM} = a + b\sqrt{E + cE^2} \quad [\text{Eqn. 4.2.1}]$$

In this expression,

E = the energy of the particle

FWHM = Full Width at Half Maximum for the photopeak

The GEB parameters *a*, *b*, and *c* were determined iteratively using a fitting routine in Mathematica. [28] Figure 4.2.4 shows a plot of the detector resolution verse energy for the energies selected.




Figure 4.2.4: Detector resolution verse energy for the isotopes chosen to calculate the GEB parameters

4.3 MIRD Phantom Models

To simulate the response of the thyroid uptake collimator on internally contaminated individuals, a series of Monte Carlo models was used. Six anthropomorphic phantoms, of varying ages and body sizes, were used in conjunction with the MCNP5 model of the thyroid uptake collimator. These phantoms can be described by their height and body mass and the mass of adipose tissue. The Body Mass Index (BMI) is a useful tool for characterizing human body size as well. The BMI is calculated by dividing the mass (kg) by the square of the height (m), and is only valid for adults older than 17 years. In general, a BMI greater than 30 indicates obesity. [37] Table 4.3.1 shows the characteristics of each human phantom used in this work.

Table 4.3.1 Characteristics of human phantoms used in MCNP simulations

| | Height (cm) | Mass (kg) | BMI | Adipose Mass (kg) |
|---|------------------------|----------------------|------------|------------------------------|
| Reference Male | 179 | 73.1 | 23 | 11 |
| Reference Female | 168 | 56.5 | 20 | 15 |
| Adipose Male | 179 | 93.7 | 30 | 22 |
| Adipose Female | 168 | 73.9 | 26 | 15 |
| Post-Menopausal Adipose Female | 168 | 85.9 | 30 | 27 |
| 10-year Androgynous Child | 140 | 32.7 | n/a | n/a |

The position of the thyroid uptake collimator can greatly influence the detection efficiency of internally deposited radionuclides. Previous MCNP modeling studies showed that the back right lung and the front right lung are the most optimal chest locations for the thyroid uptake counter. [24] In our current model, the detector was placed at both the back right and front right chest positions for the male phantom, as well as on the outer left thigh and the front of the neck. For each of the other phantom types, the front right chest position was excluded. A VisEd generated representation of the male phantom with each of the thyroid uptake probe positions is shown in Figure 4.3.1.




Figure 4.3.1 Thyroid uptake collimator positions on the Male anthropomorphic phantom

A uniformly distributed unit source of each isotope of interest (Am-241, Cs-137, Co-60, I-131, and Ir-192) was distributed in various organs throughout the phantoms. The organs selected are based on the ICRP models for inhaled dose, and include the gastro-intestinal tract and several body tissues. These organs vary slightly depending on the gender of the phantom and the presence of adipose tissue. The organs in which unit sources were distributed in the male phantom are shown in Table 4.3.2.

Table 4.3.2 Organs where unit sources were distributed in MCNP model

| Isotope | Organs |
|----------------|--|
| Cs-137 | Left Lung, Right Lung, Stomach, Small Intestines, Heart, Ascending Colon Wall, Sigmoid Colon Wall, Transverse Colon Wall, Descending Colon Wall, Bladder, Body Tissue (Torso, Head, Shoulder, Left Leg, Right Leg, Genitalia) |
| Co-60 | Left Lung, Right Lung, Stomach, Small Intestines, Heart, Ascending Colon Wall, Sigmoid Colon Wall, Transverse Colon Wall, Descending Colon Wall, Bladder, Body Tissue (Torso, Shoulder, Abdomen, Head, Left Leg, Right Leg, Genitalia), Liver |
| I-131 | Left Lung, Right Lung, Stomach, Small Intestines, Heart, Ascending Colon Wall, Sigmoid Colon Wall, Transverse Colon Wall, Descending Colon Wall, Bladder, Body Tissue (Torso, Shoulder, Abdomen, Head, Left Leg, Right Leg, Genitalia), Thyroid |
| Ir-192 | Left Lung, Right Lung, Stomach, Small Intestines, Heart, Ascending Colon Wall, Sigmoid Colon Wall, Transverse Colon Wall, Descending Colon Wall, Bladder, Body Tissue (Torso, Shoulder, Abdomen, Head, Left Leg, Right Leg, Genitalia), Liver, Left Kidney, Right Kidney, Spleen |
| Am-241 | Left Lung, Right Lung, Stomach, Small Intestines, Heart, Ascending Colon Wall, Sigmoid Colon Wall, Transverse Colon Wall, Descending Colon Wall, Bladder, Body Tissue (Torso, Shoulder, Abdomen, Head, Right Leg, Left Leg), Liver, Ribs, Pelvis, Spine, Skull, Left Leg bones, Right Leg bones, Left Arm bones, Right Arm bones, Left Kidney, Right Kidney, Left Testicle, Right Testicle, Left Clavicle, Right Clavicle, Left Scapula, Right Scapula |

The difference between the organs in the male phantom and the female phantom is the addition of the right and left breast tissue included in the body tissue category. Also, the female phantom includes the right and left ovaries rather than the testicles. The adipose phantoms include the addition of adipose tissue on the abdomen, subcutaneous adipose tissue, and adipose tissue on the upper legs. All adipose tissue is included in the body tissue grouping. A unit source is distributed in the child phantom within the same organs as the male phantom.

A source contribution tally modifier (SCX card) was used in conjunction with a pulse height tally (MCNP F8 tally) to determine the counts in the detector per a unit source distributed in each organ. The tally modifier records the origin (in this case, the source organ) of each particle that reaches the detector. This value is essentially the detector efficiency for a unit source in each organ for each isotope of concern.

Once the detector efficiency for each organ and each isotope has been computed using the MCNP model, these values were multiplied by the biokinetic modeling results. The biokinetic modeling provides the fractional organ concentration as a function of time per becquerel of intake. By summing the contributions from each source organ, the total count rate from the modeled detector was determined per becquerel of intake.

As previously mentioned, count rates are reported per becquerel of intake and per Clinical Decision Level (CDL). The MCNP input file for the male phantom with a unit source of Cs-137 in each organ is provided in Appendix C as an example.

CHAPTER 5

BIOKINETIC MODELING USING DCAL

Biokinetic modeling describes the movement of a particular isotope through the human body as a function of time. Depending on the characteristics of the isotope, it can concentrate in various organs or it can equally distribute itself throughout the body tissue.

The Dose and Risk Calculation System (DCAL) software [9] was used to determine the movement of an isotope through the human body as a function of time. Activity Calculations (ACTACAL) is part of the DCAL software, and it provides the activity as a function of time for various body compartments. The DCAL biokinetic libraries include the ICRP-66 lung model [17], the ICRP-30 gastro-intestinal tract model [12], and the ICRP-67 urinary bladder voiding model [16]. DCAL was originally created under the sponsorship of the Environmental Protection Agency (EPA) for estimating tissue dose and associated health risks associated with different environmental exposures. DCAL has been used in the development of several International Commission on Radiation Protection (ICRP) publications, in particular those with age-specific dose coefficients. [ICRP 1989, 1993, 1995a, 1995b, 1996]

DCAL was used to estimate the retention fraction in affected organs as a function of time following initial uptake. Six isotopes (Cs-137, Co-60, Am-241, I-131, Ir-192, and Sr/Y-90) were modeled using this method. DCAL calls for several parameters in generating the compartmental activities. For each isotope, inhalation was specified as the intake pathway, from an environmental source (as opposed to occupational), and activity median aerodynamic diameter (AMAD) of 1 micrometer was used. The default lung absorption type (fast, moderate, or slow) was specified for each isotope according to the International Commission on Radiological

Protection (ICRP) recommended defaults. [21] These absorption types correspond broadly to the inhalation classes D, W, and Y from the ICRP Publication 30 model. [12] This classification refers to the length of time the radioactive materials are retained in the pulmonary region. Class-D materials have a ‘half-time’ in the lungs of less than 10 days, Class-W materials have a pulmonary half-time of 10 to 100 days, and Class-Y materials have a pulmonary half-time of greater than 100 days. [41] For the nuclides Cobalt and Americium, the ICRP default absorption type for particulate aerosol is moderate. For Iodine and Cesium, the default type is fast. A default type is not specified for Iridium, so moderate was selected. The default types are summarized in Table 5.1.

Table 5.1 Default Lung Absorption Type for each nuclide

| Nuclide | Default Lung Absorption Type |
|----------------|-------------------------------------|
| Cobalt | M |
| Strontium | M |
| Yttrium | n/a |
| Iodine | F |
| Cesium | F |
| Iridium | n/a |
| Americium | M |

A comparison of the total fraction retained for each selected isotope for the first 30 days following intake is shown in Figure 5.1. The retention of an isotope in the body is a function of both the clearance class, and the isotope’s radioactive half life. As seen in the figure, Cs-137 has the highest retention rate in the body, and I-131 leaves the body with the fastest rate.




Figure 5.1 Comparison of Total Fraction Retained for each selected isotope.

DCAL shows that more than half of the initially inhaled activity is exhaled with the first breath for each of the isotopes with a moderate lung absorption class. The main organs of interest for each isotope include the lungs, stomach, small and large intestines, and urinary bladder. According to DCAL, these organs are of particular interest because large fractions of the amount originally inhaled move through the pulmonary tract and gastro-intestinal tract, depositing dose in these organs. A large fraction is retained in the intestinal tract and body tissue. The body tissue is composed of mostly abdominal tissue, but also includes breast tissue, adipose tissue, muscle tissue in the arms and legs, and genitalia. As expected, certain isotopes collect in specific body tissues – an example is the collection of I-131 in the thyroid gland. The

compartments retaining a significant fraction of the isotope were identified for each selected isotope using DCAL. These compartments are shown in Table 5.2.

Table 5.2 Body Compartments identified by DCAL for each selected isotope, bolded items are specific to that isotope

| Isotope | Body Compartments identified by DCAL |
|----------------|--|
| Cs-137 | Lungs, Stomach Content, Small Intestine Content, Upper Large Intestine Content, Lower Large Intestine Content, Blood, Body Tissue, Bladder Content |
| Co-60 | Lungs, Stomach Content, Small Intestine Content, Upper Large Intestine Content, Lower Large Intestine Content, Blood, Body Tissue, Liver , Bladder Content |
| I-131 | Lungs, Stomach Content, Small Intestine Content, Upper Large Intestine Content, Lower Large Intestine Content, Blood, Body Tissue, Thyroid , Bladder Content |
| Ir-192 | Lungs, Stomach Content, Small Intestine Content, Upper Large Intestine Content, Lower Large Intestine Content, Blood, Body Tissue, Liver, Kidneys, Spleen , Bladder Content |
| Am-241 | Lungs, Stomach Content, Small Intestine Content, Upper Large Intestine Content, Lower Large Intestine Content, Blood, Body Tissue, Cortical Bone, Trabecular Bone, Liver, Kidneys, Testes/Ovaries, Red Marrow , Bladder Content |
| Sr/Y-90 | Lungs, Stomach Content, Small Intestine Content, Upper Large Intestine Content, Lower Large Intestine Content, Blood, Body Tissue, Cortical Bone, Trabecular Bone , Bladder Content |

A graphical comparison of the lungs, body tissue, and any special organs for each isotope is shown in Figures 5.2 through 5.7. The lungs and body tissue were selected due to the high fraction retained in each of these body compartments. The total retention fraction is also included on each of these figures.




Figure 5.2 Retention of Cs-137(fast) in the lungs and body tissue and total fraction retained over first 30 days following intake.




Figure 5.3 Retention of Co-60 (moderate) in the lungs, body tissue, and liver and total fraction retained over first 30 days following intake.




Figure 5.4 Retention of I-131 (fast) in the lungs, body tissue, and thyroid and total fraction retained over first 30 days following intake.




Figure 5.5 Retention of Ir-192 (moderate) in the lungs, body tissue, liver, kidneys, and spleen and total fraction retained over first 30 days following intake.




Figure 5.6 Retention of Am-241 (moderate) in the lungs, body tissue, liver, kidneys, and bone (including red bone marrow) and total fraction retained over first 30 days following intake.




Figure 5.7 Retention of Sr/Y-90 (moderate) in the lungs, body tissue, and bone and total fraction retained over first 30 days following intake.

A fundamental component in assaying internal contamination is understanding the movement of an isotope through the body. Accordingly, the DCAL predicted organ activities are folded with the detector response for each organ and summed for each detector location. The convolution provides count rates for each detector location per unit of inhaled activity as a function of time following initial exposure.

CHAPTER 6

RESULTS

6.1 Model Validation

The MCNP model of the thyroid uptake collimator was validated in a comparison between the measured data and the MCNP calculated data. The measured slab phantom spectra for the six isotopes described in Table 3.2.1 were compared to the MCNP model prediction to check the representation of the actual detector response over a broad gamma-ray energy range. Both the total spectra and the selected Regions of Interest (ROI) around each photopeak were examined. This process was also used to create a scaling factor between the measured and calculated spectra, if needed. A representative comparison between the measured and calculated spectra for each measured isotope is shown in Figures 6.1.1 through 6.1.6. These spectra were measured with a thickness of 60mm of PMMA between the collimator and the source. Spectra for 0mm, 60mm, and 108mm for each isotope are contained in Appendix B.




Figure 6.1.1 Measured and calculated spectra for Am-241 with 60 mm PMMA




Figure 6.1.2 Measured and calculated spectra for Ba-133 with 60 mm PMMA




Figure 6.1.3 Measured and calculated spectra for Cs-137 with 60 mm PMMA




Figure 6.1.4 Measured and calculated spectra for Co-60 with 60 mm PMMA




Figure 6.1.5 Measured and calculated spectra for Mn-54 with 60 mm PMMA




Figure 6.1.6 Measured and calculated spectra for Na-22 with 60 mm PMMA

The gamma-ray photopeaks for the benchmark measurements were automatically selected using the thyroid uptake system nuclide identification software. The default calibration is set to 2keV/channel, and the nuclide selection tool calls upon preset values in the data library for each isotope. For consistency, the same ROI was used for the calculated spectra. The default ROI values for each isotope are shown in Table 6.1.1.

Table 6.1.1: Capintec default ROI values used in measured and calculated spectra

| Isotope | Default ROI (keV) |
|---------|--------------------|
| Am-241 | 49-70 |
| Ba-133 | 70-100, 334-384 |
| Cs-137 | 627-697 |
| Co-60 | 1126-1382 |
| Mn-54 | 792-878 |
| Na-22 | 480-546, 1220-1328 |

The ratio of the calculated (MCNP) count rate to the measured count rate for the gamma-ray photopeak(s) of each isotope are shown in Figures 6.1.7 through 6.1.12. The solid line in these figures show the mean ratio for the Capintec selected ROI around the photopeak.




Figure 6.1.7 Ratio of MCNP results to measured data for the 662 keV photopeak from Cs-137, with mean of 0.93




Figure 6.1.8 Ratio of MCNP results to measured data for the sum of the 1.17 and 1.33 MeV photopeaks from Co-60, with mean of 1.11




Figure 6.1.9 Ratio of MCNP results to measured data for the sum of the 0.511 and 1.27 MeV photopeaks from Na-22, with mean of 0.97




Figure 6.1.10 Ratio of MCNP results to measured data for the 835 keV photopeak from Mn-54, with mean of 1.06




Figure 6.1.11 Ratio of MCNP results to measured data for the sum of the 31, 80, and 356 keV photopeaks from Ba-133, with mean of 0.93




Figure 6.1.12 Ratio of MCNP results to measured data for the 59.5 keV photopeak from Am-241, with mean of 1.31

As seen in the figures, the ratio of the calculated spectra to measured spectra is essentially constant over all thicknesses for a given isotope. This indicates that the model of the detector is valid regardless of the attenuator thickness. This result provides confidence when using the detector in conjunction with the anthropomorphic phantoms. Any differences in chest-wall thickness between the various phantoms will not affect the detector response in the photopeaks, nor should it.

Ideally, the ratio of the calculated spectra to the measured photopeaks would be one. In actuality, a number of factors introduce error terms into the data. The error on each photopeak is dominated by the reported source activity error of 3.3%. The pulse-height bin error from MCNP and the counting error from the measured spectra were considerably smaller than the source activity error, but were also considered and included in the error calculations, illustrated by the error bars. All data for each isotope fall within 2 standard deviations of the mean.

To compensate for the differences between the measured and calculated spectra, a scaling factor (the mean ratio) is applied to the phantom results. This ‘converts’ the measured pulse-height tally to an equivalent count rate on the actual probe. The scaling factors for each isotope that is used for both benchmark measurements and phantom calculations are shown in Table 6.1.2.

Table 6.1.2 Scaling Factors for isotopes used in benchmark measurements and phantom calculations

| Isotope | Scaling Factor |
|----------------|-----------------------|
| Am-241 | 1.31 |
| Cs-137 | 0.93 |
| Co-60 | 1.11 |

The ratios for Ba-133 and Am-241 show a negative slope as the thickness of PMMA increases. The most probable cause for this is an inappropriate representation of the resolution by the GEB function at these energies. The lowest energy considered in determining the GEB

function was 0.511 MeV (Na-22). Ba-133 and Am-241 both have gamma-ray emissions at energies lower than 0.511 MeV meaning that they have a higher resolution. This is due to the fact that resolution is inversely proportional to the square-root of the gamma ray energy. [Knoll, 2002] A comparison of the spectra shows that indeed, the calculated ROIs are considerably broader than the measured spectra. This can be seen in the Slab Phantom Spectral Data, contained in Appendix B.

With the exception of Am-241, all the isotopes of greatest concern investigated herein have energies higher than 300 keV. Thus, the GEB function is adequate for the purpose and intent of this work and therefore the scaling factor also is valid. The scaling factor corrects for differences between the measured and calculated data, and provides a validated estimate of the actual detector response.

6.2 MIRD Phantom Results

In the event of an actual emergency requiring the use of this screening procedure, the operators are not expected to visually inspect the spectra to select an optimal ROI. Instead, they will simply use the Capintec nuclide identification tool, which selects the ROI channels based on data stored in the Captus 3000 data library. Thus, the following results use the scaling factor based on the Captus system default ROI selection, which was discussed in the previous section. Two of the isotopes (I-131 and Ir-192) used in the phantom simulations were not included in the benchmark measurements and validation process. As a result, scaling factors were not calculated for these two isotopes; Capintec system default ROIs were used throughout the analysis for these two isotopes.

Each of the six isotopes listed in Table 3.4.1 were uniformly distributed in the six phantom types. The results for the Male phantom contaminated with Cs-137 are shown in Table

6.2.1. The values are given in count rate (counts per minute) per becquerel of intake activity. Results for the remaining phantom types contaminated with Cs-137 and each of the other four isotopes are provided in Appendix D.

Table 6.2.1 Count rate per Bq calculated for the Male phantom contaminated with Cs-137

| | | Back Right Lung | Front Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 1.85E-04 | 1.77E-04 | 1.51E-05 | 1.31E-06 |
| | 1 | 4.29E-04 | 4.63E-04 | 5.07E-04 | 2.47E-04 |
| | 2 | 4.11E-04 | 4.48E-04 | 5.20E-04 | 2.54E-04 |
| | 3 | 3.94E-04 | 4.30E-04 | 5.08E-04 | 2.49E-04 |
| | 4 | 3.83E-04 | 4.19E-04 | 4.99E-04 | 2.44E-04 |
| | 5 | 3.76E-04 | 4.11E-04 | 4.91E-04 | 2.40E-04 |
| | 6 | 3.71E-04 | 4.05E-04 | 4.84E-04 | 2.37E-04 |
| | 7 | 3.66E-04 | 4.00E-04 | 4.79E-04 | 2.35E-04 |
| | 8 | 3.63E-04 | 3.97E-04 | 4.74E-04 | 2.32E-04 |
| | 9 | 3.60E-04 | 3.93E-04 | 4.70E-04 | 2.30E-04 |
| | 10 | 3.57E-04 | 3.90E-04 | 4.66E-04 | 2.28E-04 |
| | 20 | 3.33E-04 | 3.64E-04 | 4.36E-04 | 2.13E-04 |
| | 30 | 3.13E-04 | 3.42E-04 | 4.09E-04 | 2.00E-04 |

As discussed, the fast absorption type of Cs-137 rapidly distributes itself through the body tissue and is quickly out of the lung cavities. Analysis of the data for Cs-137 shows that after one day, the neck provides a higher count rate per becquerel than the front and back lung positions. The thigh shows a lower count rate; however, it is the same order of magnitude as the lung and neck count rates.

In the case of Cs-137, the variability between body type and detector response is much more pronounced than for the other isotopes. Figure 6.2.1 shows a graphical comparison of the count rates resulting from each phantom type contaminated with Cs-137 with the detector on the

neck. The other detector positions (back right lung and thigh) show a similar distribution, with a lower count rate.




Figure 6.2.1 Comparison of count rate per phantom type for Cs-137, with detector positioned on the neck

An analysis of the various phantom results shows that in general, the highest count rate is found in the child. This is expected as the child has the least amount of tissue, or attenuating material, between the isotope and the detector. The lowest count rate is found in one of the adipose phantoms, usually the Post-Menopausal Adipose Female. The Post-Menopausal Adipose Female has more tissue, resulting in more attenuation and absorption of the gamma ray photons before they reach the detector crystal. While it is tempting to make such generalities about the effects of body type on the detector response, in actuality the isotope has just as much impact on the count rate.

For the case of I-131, the count rates are more similar between the phantom types, and in fact, the child shows the lowest count rate per becquerel. As discussed, I-131 is rapidly absorbed by the thyroid gland. A child has a smaller thyroid gland than an adult, causing it to become saturated with I-131 before an adult's thyroid. [42] Figure 6.2.2 shows the increasing count rate per Bq for the neck detector position one, three, and ten days following the initial intake.




Figure 6.2.2 Count Rate per Bq of intake of I-131 for the neck position

A large fraction of Co-60 intake remains in the lungs, and this is reflected in the higher count rate found at the back right lung position of the detector. In addition, there is little variation between phantom types for Co-60. The Reference Male and Reference Female phantoms have similar response, as do the adipose phantoms. A comparison of the detector position and phantom type for Co-60 is shown in Figure 6.2.3.




Figure 6.2.3 Comparison of detector position and phantom type for Co-60, 3 days after intake

Ir-192 is similar to Co-60 in that they both have moderate lung absorption types; consequently, the most efficient measurement location is the back right lung for each phantom type. A significant portion of the uptake of Ir-192 goes to the blood and as a result, the majority of the counts originate in the liver, heart, and body tissue. The count rate as a function of time for the various phantom types contaminated with Ir-192 is shown in Figure 6.2.4.




Figure 6.2.4 Count rate as a function of time for each phantom type contaminated with Ir-192

The effects of body type on the detector response are also similar between Co-60 and Ir-192. Similar phantom types display similar count rates: the adipose phantoms show the lowest count rate, but there is little variability between each adipose phantom. The reference male and reference female show similar count rates. Also, as seen in Cs-137 and Co-60, the highest count rate for Ir-192 was exhibited in the child phantom.

Am-241 showed the lowest count rate per Bq of activity. Due to the low energy of the gamma-ray emission (59.5keV) only a small fraction of the particles travel to the detector. Due to this, the count rate per Bq is several orders of magnitude less than the other isotopes. In addition, the dose coefficient for Am-241 is much lower than the other isotopes investigated in this work. As a result, the count rate due to an intake of Am-241 that would result in a 25 rem committed effective dose by inhalation is less than one count per minute for the male phantom

for the back lung position and less than 0.01 counts per minute for the neck and thigh position in the male phantom for all times modeled.

The statistical error of the computational models was the main source of error for each of the phantom results. The total bin error for each tally was generally less than 1%.

Monte Carlo simulations were also performed using Strontium-90 and the male phantom type. Strontium-90 emits a beta spectrum with an average beta energy of 934 keV and exists in secular equilibrium with Yttrium-90 which emits a beta spectrum with an average beta energy of 196 keV. [8] Electrons were generated in the source organs, and were also transported in the model. Bremsstrahlung photons were also generated and tracked, and both electrons and photons were tallied in the detector crystal. The results of the simulation showed that the thyroid uptake collimator was unable to detect significant amounts of Sr/Y-90, and on the basis of these results the other phantom types were not simulated.

6.3 Consideration of Background Spectra

Thyroid Uptake Systems are built with collimators for the purpose of shielding background and obtaining a spectrum from a fairly localized area. In the event of a RDD, there could be widespread contamination surrounding the measurement areas. In an emergency situation, it is possible, though not likely, that external contamination may still be present on the skin or clothing of individuals being assessed. In this case, the collimator provides a basic advantage by attenuating a significant amount of radiation emitted from external contamination. For this work, external contamination on the victims was not considered and not included in the phantom models. The only source of background is assumed to originate from the surroundings,

not the individual. To thoroughly understand the effect that high background rates might have on assessing internal contamination, the following analysis was performed.

Several background measurements were collected at the Emory University Hospital Nuclear Medicine Injection Room in Atlanta, Georgia. In this room, nuclear medicine procedures involving various isotopes are conducted. The room has a relatively high background rate since contaminated objects (needles, towels, gloves, etc) are disposed of in a lead shielded box stored in the room. A Captus 2000 Thyroid Uptake System was housed in this room, and background count rate levels were collected using this machine. The Captus 2000 and the Captus 3000 are very similar in that each includes a thyroid uptake collimator with a 2" by 2" NaI crystal and a lead and antimony collimator. One major difference between the two systems is that the Captus 2000 does not include the nuclide identification tool. As a result, background rates were collected for the entire spectrum only.

The average background rate in this room was 2846 counts per minute. Counts were taken for 10 minutes of live time. In the Georgia Tech laboratory that held the Captus 3000 Thyroid Uptake System, the background rate was significantly lower. The average background rate was approximately 1700 counts per minute, recorded over 10 minutes of live time. One background spectrum collected in the Georgia Tech laboratory is shown in Figure 6.3.1. The spectrum has been scaled up by a factor of two to approximate a more realistic hospital background. This scaled spectrum was used in the calculations of MDA and the DLs.




Figure 6.3.1 Background spectrum collected at Georgia Tech laboratory

6.4 Decision Levels

The DL for determining whether activity is present was calculated for the thyroid uptake collimator. The DL is a function of the background rate and counting times; thus is is dependent on the isotope. The background rate in the Capintec ROI was used for each isotope. The DL values represent the minimum count rates above background to assume that activity is present. Table 6.4.1 shows the DL necessary for a one minute counting time for a factor of five times the scaled up Georgia Tech background spectrum (this is essentially 10 times the average background count rate). This table also includes the default ROI values for each isotope used in conjunction with the phantoms, and the background count rate within that ROI.

Table 6.4.1 Decision Levels for one minute counting times for the thyroid uptake collimator

| Isotope | Default ROI (keV) | 5 x background count rate in ROI | Decision Level for one minute counting time (Count rate above background) |
|----------------|--------------------------|---|--|
| Am-241 | 49-70 | 5340 | 40 |
| Cs-137 | 627-697 | 6430 | 44 |
| Co-60 | 1126-1382 | 5120 | 39 |
| Ir-192 | 287-335 | 9230 | 52 |
| I-131 | 338-391 | 8500 | 50 |

As anticipated, the minimum count rate required to determine the presence of activity with 95% confidence increases as the background rate increases, and decreases as counting time increases. In the event of an RDD, the minimum counting time will be desired to maximize the number of people assessed in a given amount of time. By comparing the decision level to the calculated count rate due to an intake of one CDL for the male phantom, it has been determined that one minute is more than adequate to detect Cs-137, Co-60, or Ir-192 from the back right lung position. I-131 can be detected from the back right lung position with a one minute counting time for the first two days following intake. Subsequent to that, the neck is a more optimal position. If the detector is placed over the neck, a one minute counting time is sufficient to detect one CDL of Cs-137 and I-131 as well. The thigh is not an adequate position for assaying I-131 or Am-241. For Co-60, Cs-137, and Ir-192, a one minute counting time is sufficient to detect an intake of one CDL or greater for the thigh position. Am-241 is not detectable above background at any of the studied detector positions. A comparison of the count rate per CDL and the DL for a one minute counting time is shown in Table 6.4.2 for each isotope and the optimal detector position. From this comparison, it is clear that Am-241 is undetectable, and the other four isotopes exceed the decision level by at least two orders of magnitude.

Table 6.4.2 Count rate per CDL for optimal detector position on male phantom, 3 days following initial intake

| Isotope | Detector Position | Count Rate (cpm) per CDL | Decision Level for one minute counting time (Count rate above background) |
|----------------|--------------------------|-------------------------------------|--|
| Am-241 | Back Right Lung | 0.146 | 40 |
| Cs-137 | Neck | 27600 | 44 |
| Co-60 | Back Right Lung | 2390 | 39 |
| Ir-192 | Back Right Lung | 4670 | 52 |
| I-131 | Neck | 2530 | 50 |

With 27 kg of adipose tissue, the Post-Menopausal Adipose Female phantom contains the most adipose tissue, and as a result generally shows the lowest count rates per Bq of intake. By examining the Post-Menopausal Adipose Female, an upper limit to the minimum necessary counting time can be estimated. A counting time of one minute is sufficient to detect one CDL of Co-60, Ir-192, and Cs-137 when the detector is placed over the back right lung. For I-131 and Cs-137, the detector should be placed over the front neck to achieve maximum efficiency. One minute is a sufficient amount of time to detect I-131 and Cs-137 when the detector is placed on the front neck of the Post-Menopausal Adipose Female phantom.

6.5 Personal Contamination Screening Threshold Determination

As previously discussed, one Clinical Decision Level is assumed to be an intake which leads to 25 rem committed effective dose. The actual use of the Clinical Decision Level will be made by governing bodies at the time of an event. The dose coefficients for inhalation for each isotope are from ICRP 72 and were determined using Rad Toolbox [8]. The dose coefficients are shown in Table 6.5.1.

Table 6.5.1 Dose coefficients for inhalation for one CDL

| | Adult (Bq/CDL) | 10 year Child (Bq/CDL) |
|----------|-------------------|---------------------------|
| Cs-137 F | 5.43E+07 | 1.25E+08 |
| Co-60 M | 2.50E+07 | 1.67E+07 |
| I-131 F | 3.38E+07 | 1.32E+07 |
| Ir-192 M | 4.81E+07 | 3.29E+07 |
| Am-241 M | 5.95E+03 | 6.25E+03 |

Count rates per CDL are given for each isotope and phantom type in Tables 6.5.2 through 6.5.31.

Table 6.5.2 Count rate per CDL for the Male phantom contaminated with Cs-137

| | | Back Right Lung | Front Right Lung | Neck | Thigh |
|--------------------------------|----|-----------------|------------------|-------------|-------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 1.01E+04 | 9.65E+03 | 8.20E+02 | 7.11E+01 |
| | 1 | 2.33E+04 | 2.52E+04 | 2.76E+04 | 1.34E+04 |
| | 2 | 2.24E+04 | 2.43E+04 | 2.82E+04 | 1.38E+04 |
| | 3 | 2.14E+04 | 2.34E+04 | 2.76E+04 | 1.35E+04 |
| | 4 | 2.08E+04 | 2.27E+04 | 2.71E+04 | 1.33E+04 |
| | 5 | 2.04E+04 | 2.23E+04 | 2.67E+04 | 1.31E+04 |
| | 6 | 2.01E+04 | 2.20E+04 | 2.63E+04 | 1.29E+04 |
| | 7 | 1.99E+04 | 2.18E+04 | 2.60E+04 | 1.27E+04 |
| | 8 | 1.97E+04 | 2.16E+04 | 2.58E+04 | 1.26E+04 |
| | 9 | 1.95E+04 | 2.14E+04 | 2.56E+04 | 1.25E+04 |
| | 10 | 1.94E+04 | 2.12E+04 | 2.54E+04 | 1.24E+04 |
| | 20 | 1.81E+04 | 1.98E+04 | 2.37E+04 | 1.16E+04 |
| | 30 | 1.70E+04 | 1.86E+04 | 2.22E+04 | 1.09E+04 |

Table 6.5.3 Count rate per CDL for the Female phantom contaminated with Cs-137

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 9.38E+03 | 8.10E+02 | 8.62E+01 |
| | 1 | 2.94E+04 | 3.47E+04 | 1.29E+04 |
| | 2 | 2.87E+04 | 3.56E+04 | 1.32E+04 |
| | 3 | 2.77E+04 | 3.49E+04 | 1.30E+04 |
| | 4 | 2.70E+04 | 3.42E+04 | 1.27E+04 |
| | 5 | 2.65E+04 | 3.37E+04 | 1.25E+04 |
| | 6 | 2.62E+04 | 3.32E+04 | 1.24E+04 |
| | 7 | 2.59E+04 | 3.29E+04 | 1.22E+04 |
| | 8 | 2.56E+04 | 3.26E+04 | 1.21E+04 |
| | 9 | 2.54E+04 | 3.23E+04 | 1.20E+04 |
| | 10 | 2.52E+04 | 3.20E+04 | 1.19E+04 |
| | 20 | 2.35E+04 | 2.99E+04 | 1.11E+04 |
| | 30 | 2.21E+04 | 2.81E+04 | 1.04E+04 |

Table 6.5.4 Count rate per CDL for the Adipose Male phantom contaminated with Cs-137

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 6.64E+03 | 5.59E+02 | 3.49E+01 |
| | 1 | 2.00E+04 | 3.15E+04 | 1.25E+04 |
| | 2 | 1.95E+04 | 3.24E+04 | 1.28E+04 |
| | 3 | 1.88E+04 | 3.17E+04 | 1.26E+04 |
| | 4 | 1.83E+04 | 3.11E+04 | 1.23E+04 |
| | 5 | 1.80E+04 | 3.06E+04 | 1.21E+04 |
| | 6 | 1.77E+04 | 3.02E+04 | 1.20E+04 |
| | 7 | 1.75E+04 | 2.99E+04 | 1.19E+04 |
| | 8 | 1.73E+04 | 2.96E+04 | 1.17E+04 |
| | 9 | 1.72E+04 | 2.94E+04 | 1.16E+04 |
| | 10 | 1.70E+04 | 2.91E+04 | 1.15E+04 |
| | 20 | 1.59E+04 | 2.72E+04 | 1.08E+04 |
| | 30 | 1.49E+04 | 2.55E+04 | 1.01E+04 |

Table 6.5.5 Count rate per CDL for the Adipose Female phantom contaminated with Cs-137

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 7.00E+03 | 6.21E+02 | 5.13E+01 |
| | 1 | 2.29E+04 | 3.06E+04 | 1.79E+04 |
| | 2 | 2.24E+04 | 3.14E+04 | 1.85E+04 |
| | 3 | 2.16E+04 | 3.07E+04 | 1.81E+04 |
| | 4 | 2.11E+04 | 3.01E+04 | 1.77E+04 |
| | 5 | 2.07E+04 | 2.97E+04 | 1.75E+04 |
| | 6 | 2.04E+04 | 2.93E+04 | 1.72E+04 |
| | 7 | 2.02E+04 | 2.90E+04 | 1.71E+04 |
| | 8 | 2.00E+04 | 2.87E+04 | 1.69E+04 |
| | 9 | 1.98E+04 | 2.84E+04 | 1.67E+04 |
| | 10 | 1.96E+04 | 2.82E+04 | 1.66E+04 |
| | 20 | 1.84E+04 | 2.64E+04 | 1.55E+04 |
| | 30 | 1.72E+04 | 2.47E+04 | 1.46E+04 |

Table 6.5.6 Count rate per CDL for the Post-Menopausal Adipose Female phantom contaminated with Cs-137

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 1.14E+03 | 4.12E+02 | 4.57E+01 |
| | 1 | 5.98E+03 | 8.43E+03 | 3.01E+03 |
| | 2 | 5.97E+03 | 8.61E+03 | 3.09E+03 |
| | 3 | 5.79E+03 | 8.42E+03 | 3.03E+03 |
| | 4 | 5.66E+03 | 8.25E+03 | 2.97E+03 |
| | 5 | 5.56E+03 | 8.12E+03 | 2.92E+03 |
| | 6 | 5.49E+03 | 8.02E+03 | 2.88E+03 |
| | 7 | 5.43E+03 | 7.93E+03 | 2.85E+03 |
| | 8 | 5.37E+03 | 7.85E+03 | 2.82E+03 |
| | 9 | 5.33E+03 | 7.78E+03 | 2.80E+03 |
| | 10 | 5.28E+03 | 7.72E+03 | 2.78E+03 |
| | 20 | 4.94E+03 | 7.21E+03 | 2.59E+03 |
| | 30 | 4.63E+03 | 6.77E+03 | 2.43E+03 |

Table 6.5.7 Count rate per CDL for the Child phantom contaminated with Cs-137

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 2.85E+04 | 2.37E+03 | 0.00E+00 |
| | 1 | 8.75E+04 | 9.29E+04 | 4.83E+04 |
| | 2 | 8.53E+04 | 9.52E+04 | 4.98E+04 |
| | 3 | 8.21E+04 | 9.32E+04 | 4.88E+04 |
| | 4 | 8.01E+04 | 9.14E+04 | 4.79E+04 |
| | 5 | 7.87E+04 | 9.00E+04 | 4.71E+04 |
| | 6 | 7.76E+04 | 8.88E+04 | 4.65E+04 |
| | 7 | 7.67E+04 | 8.78E+04 | 4.60E+04 |
| | 8 | 7.59E+04 | 8.70E+04 | 4.56E+04 |
| | 9 | 7.53E+04 | 8.62E+04 | 4.52E+04 |
| | 10 | 7.47E+04 | 8.55E+04 | 4.48E+04 |
| | 20 | 6.98E+04 | 7.99E+04 | 4.19E+04 |
| | 30 | 6.55E+04 | 7.50E+04 | 3.93E+04 |

Table 6.5.8 Count rate per CDL calculated for the Male phantom contaminated with Co-60

| | | Back Right Lung | Front Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 6.91E+03 | 6.63E+03 | 1.60E+03 | 1.64E+02 |
| | 1 | 3.24E+03 | 3.32E+03 | 1.31E+03 | 5.09E+02 |
| | 2 | 2.66E+03 | 2.69E+03 | 1.21E+03 | 5.04E+02 |
| | 3 | 2.39E+03 | 2.41E+03 | 1.13E+03 | 4.59E+02 |
| | 4 | 2.26E+03 | 2.27E+03 | 1.08E+03 | 4.25E+02 |
| | 5 | 2.18E+03 | 2.19E+03 | 1.03E+03 | 4.01E+02 |
| | 6 | 2.12E+03 | 2.13E+03 | 9.98E+02 | 3.83E+02 |
| | 7 | 2.08E+03 | 2.08E+03 | 9.69E+02 | 3.69E+02 |
| | 8 | 2.03E+03 | 2.04E+03 | 9.43E+02 | 3.57E+02 |
| | 9 | 2.00E+03 | 2.00E+03 | 9.19E+02 | 3.47E+02 |
| | 10 | 1.96E+03 | 1.96E+03 | 8.98E+02 | 3.37E+02 |
| | 20 | 1.70E+03 | 1.70E+03 | 7.69E+02 | 2.85E+02 |
| | 30 | 1.54E+03 | 1.54E+03 | 7.10E+02 | 2.68E+02 |

Table 6.5.9 Count rate per CDL calculated for the Female phantom contaminated with Co-60

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 6.59E+03 | 1.61E+03 | 1.92E+02 |
| | 1 | 3.21E+03 | 1.58E+03 | 5.21E+02 |
| | 2 | 2.69E+03 | 1.52E+03 | 5.10E+02 |
| | 3 | 2.44E+03 | 1.44E+03 | 4.62E+02 |
| | 4 | 2.31E+03 | 1.37E+03 | 4.27E+02 |
| | 5 | 2.23E+03 | 1.32E+03 | 4.03E+02 |
| | 6 | 2.17E+03 | 1.27E+03 | 3.85E+02 |
| | 7 | 2.12E+03 | 1.23E+03 | 3.71E+02 |
| | 8 | 2.08E+03 | 1.20E+03 | 3.59E+02 |
| | 9 | 2.04E+03 | 1.17E+03 | 3.49E+02 |
| | 10 | 2.00E+03 | 1.14E+03 | 3.39E+02 |
| | 20 | 1.73E+03 | 9.72E+02 | 2.87E+02 |
| | 30 | 1.57E+03 | 9.02E+02 | 2.69E+02 |

Table 6.5.10 Count rate per CDL calculated for the Adipose Male phantom contaminated with Co-60

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 4.79E+03 | 1.18E+03 | 9.96E+01 |
| | 1 | 2.32E+03 | 1.28E+03 | 4.53E+02 |
| | 2 | 1.95E+03 | 1.28E+03 | 4.63E+02 |
| | 3 | 1.78E+03 | 1.22E+03 | 4.28E+02 |
| | 4 | 1.68E+03 | 1.17E+03 | 3.98E+02 |
| | 5 | 1.62E+03 | 1.12E+03 | 3.77E+02 |
| | 6 | 1.58E+03 | 1.08E+03 | 3.61E+02 |
| | 7 | 1.54E+03 | 1.05E+03 | 3.47E+02 |
| | 8 | 1.51E+03 | 1.02E+03 | 3.36E+02 |
| | 9 | 1.48E+03 | 9.93E+02 | 3.25E+02 |
| | 10 | 1.46E+03 | 9.68E+02 | 3.17E+02 |
| | 20 | 1.26E+03 | 8.25E+02 | 2.67E+02 |
| | 30 | 1.14E+03 | 7.68E+02 | 2.52E+02 |

Table 6.5.11 Count rate per CDL calculated for the Adipose Female phantom contaminated with Co-60

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 4.95E+03 | 1.27E+03 | 1.29E+02 |
| | 1 | 2.48E+03 | 1.31E+03 | 5.58E+02 |
| | 2 | 2.10E+03 | 1.30E+03 | 5.93E+02 |
| | 3 | 1.91E+03 | 1.24E+03 | 5.63E+02 |
| | 4 | 1.81E+03 | 1.18E+03 | 5.31E+02 |
| | 5 | 1.74E+03 | 1.13E+03 | 5.06E+02 |
| | 6 | 1.70E+03 | 1.10E+03 | 4.85E+02 |
| | 7 | 1.66E+03 | 1.06E+03 | 4.67E+02 |
| | 8 | 1.62E+03 | 1.03E+03 | 4.52E+02 |
| | 9 | 1.59E+03 | 1.00E+03 | 4.38E+02 |
| | 10 | 1.56E+03 | 9.79E+02 | 4.26E+02 |
| | 20 | 1.35E+03 | 8.34E+02 | 3.60E+02 |
| | 30 | 1.22E+03 | 7.76E+02 | 3.39E+02 |

Table 6.5.12 Count rate per CDL calculated for the Post-Menopausal Adipose Female phantom contaminated with Co-60

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 5.07E+03 | 1.33E+03 | 1.24E+02 |
| | 1 | 2.47E+03 | 1.40E+03 | 3.98E+02 |
| | 2 | 2.07E+03 | 1.40E+03 | 3.96E+02 |
| | 3 | 1.88E+03 | 1.34E+03 | 3.61E+02 |
| | 4 | 1.78E+03 | 1.28E+03 | 3.35E+02 |
| | 5 | 1.72E+03 | 1.23E+03 | 3.17E+02 |
| | 6 | 1.67E+03 | 1.18E+03 | 3.03E+02 |
| | 7 | 1.63E+03 | 1.15E+03 | 2.92E+02 |
| | 8 | 1.60E+03 | 1.11E+03 | 2.82E+02 |
| | 9 | 1.57E+03 | 1.08E+03 | 2.74E+02 |
| | 10 | 1.54E+03 | 1.06E+03 | 2.66E+02 |
| | 20 | 1.33E+03 | 9.01E+02 | 2.25E+02 |
| | 30 | 1.21E+03 | 8.38E+02 | 2.12E+02 |

Table 6.5.13 Count rate per CDL calculated for the Child phantom contaminated with Co-60

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 5.60E+03 | 1.11E+03 | 3.19E+02 |
| | 1 | 2.75E+03 | 1.22E+03 | 5.00E+02 |
| | 2 | 2.30E+03 | 1.16E+03 | 4.59E+02 |
| | 3 | 2.08E+03 | 1.09E+03 | 4.07E+02 |
| | 4 | 1.97E+03 | 1.03E+03 | 3.74E+02 |
| | 5 | 1.90E+03 | 9.88E+02 | 3.52E+02 |
| | 6 | 1.85E+03 | 9.53E+02 | 3.37E+02 |
| | 7 | 1.81E+03 | 9.23E+02 | 3.26E+02 |
| | 8 | 1.77E+03 | 8.96E+02 | 3.16E+02 |
| | 9 | 1.73E+03 | 8.72E+02 | 3.07E+02 |
| | 10 | 1.70E+03 | 8.51E+02 | 2.99E+02 |
| | 20 | 1.48E+03 | 7.25E+02 | 2.54E+02 |
| | 30 | 1.34E+03 | 6.74E+02 | 2.37E+02 |

Table 6.5.14 Count rate per CDL calculated for the Male phantom contaminated with Am-241

| | | Back Right Lung | Front Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 4.26E-01 | 4.07E-01 | 2.83E-03 | 0.00E+00 |
| | 1 | 1.90E-01 | 1.54E-01 | 8.60E-03 | 3.86E-03 |
| | 2 | 1.58E-01 | 1.21E-01 | 6.05E-03 | 2.63E-03 |
| | 3 | 1.46E-01 | 1.08E-01 | 5.10E-03 | 1.99E-03 |
| | 4 | 1.42E-01 | 1.03E-01 | 4.76E-03 | 1.73E-03 |
| | 5 | 1.40E-01 | 1.00E-01 | 4.65E-03 | 1.63E-03 |
| | 6 | 1.39E-01 | 9.85E-02 | 4.63E-03 | 1.61E-03 |
| | 7 | 1.38E-01 | 9.72E-02 | 4.64E-03 | 1.61E-03 |
| | 8 | 1.38E-01 | 9.60E-02 | 4.66E-03 | 1.62E-03 |
| | 9 | 1.38E-01 | 9.49E-02 | 4.69E-03 | 1.63E-03 |
| | 10 | 1.37E-01 | 9.39E-02 | 4.71E-03 | 1.64E-03 |
| | 20 | 1.34E-01 | 8.46E-02 | 4.96E-03 | 1.76E-03 |
| | 30 | 1.33E-01 | 7.71E-02 | 5.13E-03 | 1.85E-03 |

Table 6.5.15 Count rate per CDL calculated for the Female phantom contaminated with Am-241

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 3.87E-01 | 3.36E-03 | 0.00E+00 |
| | 1 | 1.95E-01 | 9.10E-03 | 4.16E-03 |
| | 2 | 1.68E-01 | 6.41E-03 | 2.83E-03 |
| | 3 | 1.59E-01 | 5.41E-03 | 2.10E-03 |
| | 4 | 1.56E-01 | 5.05E-03 | 1.80E-03 |
| | 5 | 1.55E-01 | 4.93E-03 | 1.69E-03 |
| | 6 | 1.54E-01 | 4.91E-03 | 1.66E-03 |
| | 7 | 1.55E-01 | 4.92E-03 | 1.65E-03 |
| | 8 | 1.55E-01 | 4.94E-03 | 1.66E-03 |
| | 9 | 1.55E-01 | 4.97E-03 | 1.67E-03 |
| | 10 | 1.55E-01 | 4.99E-03 | 1.69E-03 |
| | 20 | 1.58E-01 | 5.23E-03 | 1.81E-03 |
| | 30 | 1.62E-01 | 5.40E-03 | 1.90E-03 |

Table 6.5.16 Count rate per CDL calculated for the Adipose Male phantom contaminated with Am-241

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 2.47E-01 | 2.69E-03 | 2.69E-03 |
| | 1 | 1.25E-01 | 8.20E-03 | 8.20E-03 |
| | 2 | 1.08E-01 | 5.77E-03 | 5.77E-03 |
| | 3 | 1.02E-01 | 4.86E-03 | 4.86E-03 |
| | 4 | 1.00E-01 | 4.54E-03 | 4.54E-03 |
| | 5 | 9.95E-02 | 4.43E-03 | 4.43E-03 |
| | 6 | 9.94E-02 | 4.41E-03 | 4.41E-03 |
| | 7 | 9.95E-02 | 4.42E-03 | 4.42E-03 |
| | 8 | 9.96E-02 | 4.44E-03 | 4.44E-03 |
| | 9 | 9.98E-02 | 4.47E-03 | 4.47E-03 |
| | 10 | 1.00E-01 | 4.49E-03 | 4.49E-03 |
| | 20 | 1.02E-01 | 4.72E-03 | 4.72E-03 |
| | 30 | 1.04E-01 | 4.89E-03 | 4.89E-03 |

Table 6.5.17 Count rate per CDL calculated for the Adipose Female phantom contaminated with Am-241

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 3.06E-01 | 3.13E-03 | 7.94E-06 |
| | 1 | 1.52E-01 | 8.49E-03 | 6.94E-03 |
| | 2 | 1.31E-01 | 5.98E-03 | 4.77E-03 |
| | 3 | 1.23E-01 | 5.05E-03 | 3.80E-03 |
| | 4 | 1.20E-01 | 4.71E-03 | 3.43E-03 |
| | 5 | 1.20E-01 | 4.60E-03 | 3.30E-03 |
| | 6 | 1.19E-01 | 4.58E-03 | 3.27E-03 |
| | 7 | 1.19E-01 | 4.59E-03 | 3.28E-03 |
| | 8 | 1.19E-01 | 4.61E-03 | 3.30E-03 |
| | 9 | 1.19E-01 | 4.63E-03 | 3.33E-03 |
| | 10 | 1.20E-01 | 4.66E-03 | 3.36E-03 |
| | 20 | 1.21E-01 | 4.88E-03 | 3.61E-03 |
| | 30 | 1.24E-01 | 5.04E-03 | 3.80E-03 |

Table 6.5.18 Count rate per CDL calculated for the Post-Menopausal Adipose Female phantom contaminated with Am-241

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 2.67E-01 | 3.41E-03 | 0.00E+00 |
| | 1 | 1.36E-01 | 8.98E-03 | 3.14E-03 |
| | 2 | 1.18E-01 | 6.33E-03 | 2.14E-03 |
| | 3 | 1.12E-01 | 5.35E-03 | 1.59E-03 |
| | 4 | 1.10E-01 | 4.99E-03 | 1.35E-03 |
| | 5 | 1.09E-01 | 4.87E-03 | 1.27E-03 |
| | 6 | 1.09E-01 | 4.85E-03 | 1.24E-03 |
| | 7 | 1.09E-01 | 4.86E-03 | 1.24E-03 |
| | 8 | 1.09E-01 | 4.88E-03 | 1.25E-03 |
| | 9 | 1.09E-01 | 4.90E-03 | 1.26E-03 |
| | 10 | 1.09E-01 | 4.93E-03 | 1.27E-03 |
| | 20 | 1.12E-01 | 5.16E-03 | 1.36E-03 |
| | 30 | 1.15E-01 | 5.33E-03 | 1.43E-03 |

Table 6.5.19 Count rate per CDL calculated for the Child phantom contaminated with Am-241

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 6.92E-01 | 1.17E-02 | 0.00E+00 |
| | 1 | 3.14E-01 | 2.12E-02 | 7.19E-03 |
| | 2 | 2.61E-01 | 1.51E-02 | 4.71E-03 |
| | 3 | 2.42E-01 | 1.28E-02 | 3.23E-03 |
| | 4 | 2.34E-01 | 1.19E-02 | 2.59E-03 |
| | 5 | 2.31E-01 | 1.17E-02 | 2.35E-03 |
| | 6 | 2.29E-01 | 1.16E-02 | 2.27E-03 |
| | 7 | 2.29E-01 | 1.16E-02 | 2.25E-03 |
| | 8 | 2.28E-01 | 1.16E-02 | 2.26E-03 |
| | 9 | 2.27E-01 | 1.17E-02 | 2.27E-03 |
| | 10 | 2.27E-01 | 1.17E-02 | 2.29E-03 |
| | 20 | 2.23E-01 | 1.21E-02 | 2.45E-03 |
| | 30 | 2.21E-01 | 1.24E-02 | 2.57E-03 |

Table 6.5.20 Count rate per CDL calculated for the Male phantom contaminated with I-131

| | | Back Right Lung | Front Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 9.67E+03 | 9.28E+03 | 8.16E+01 | 6.41E+00 |
| | 1 | 1.13E+03 | 1.11E+03 | 2.91E+03 | 3.45E+01 |
| | 2 | 3.76E+02 | 3.91E+02 | 2.75E+03 | 2.07E+01 |
| | 3 | 1.58E+02 | 1.81E+02 | 2.53E+03 | 2.73E+01 |
| | 4 | 9.16E+01 | 1.15E+02 | 2.32E+03 | 3.32E+01 |
| | 5 | 7.25E+01 | 9.53E+01 | 2.12E+03 | 3.76E+01 |
| | 6 | 6.82E+01 | 8.96E+01 | 1.95E+03 | 4.06E+01 |
| | 7 | 6.80E+01 | 8.79E+01 | 1.78E+03 | 4.25E+01 |
| | 8 | 6.83E+01 | 8.67E+01 | 1.63E+03 | 4.34E+01 |
| | 9 | 6.82E+01 | 8.51E+01 | 1.49E+03 | 4.37E+01 |
| | 10 | 6.74E+01 | 8.30E+01 | 1.37E+03 | 4.33E+01 |
| | 20 | 4.26E+01 | 4.93E+01 | 5.59E+02 | 2.77E+01 |
| | 30 | 2.06E+01 | 2.34E+01 | 2.25E+02 | 1.34E+01 |

Table 6.5.21 Count rate per CDL calculated for the Female phantom contaminated with I-131

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 8.98E+03 | 8.03E+01 | 8.48E+00 |
| | 1 | 1.07E+03 | 2.42E+03 | 3.20E+01 |
| | 2 | 3.67E+02 | 2.28E+03 | 1.91E+01 |
| | 3 | 1.69E+02 | 2.10E+03 | 2.51E+01 |
| | 4 | 1.10E+02 | 1.93E+03 | 3.05E+01 |
| | 5 | 9.48E+01 | 1.77E+03 | 3.45E+01 |
| | 6 | 9.24E+01 | 1.63E+03 | 3.73E+01 |
| | 7 | 9.31E+01 | 1.49E+03 | 3.90E+01 |
| | 8 | 9.37E+01 | 1.37E+03 | 3.99E+01 |
| | 9 | 9.35E+01 | 1.25E+03 | 4.01E+01 |
| | 10 | 9.23E+01 | 1.15E+03 | 3.98E+01 |
| | 20 | 5.80E+01 | 4.74E+02 | 2.54E+01 |
| | 30 | 2.80E+01 | 1.92E+02 | 1.23E+01 |

Table 6.5.22 Count rate per CDL calculated for the Adipose Male phantom contaminated with I-131

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 6.18E+03 | 5.98E+01 | 3.62E+00 |
| | 1 | 7.37E+02 | 2.54E+03 | 3.05E+01 |
| | 2 | 2.51E+02 | 2.41E+03 | 1.83E+01 |
| | 3 | 1.14E+02 | 2.21E+03 | 2.43E+01 |
| | 4 | 7.37E+01 | 2.03E+03 | 2.96E+01 |
| | 5 | 6.29E+01 | 1.86E+03 | 3.36E+01 |
| | 6 | 6.10E+01 | 1.71E+03 | 3.63E+01 |
| | 7 | 6.14E+01 | 1.56E+03 | 3.80E+01 |
| | 8 | 6.18E+01 | 1.43E+03 | 3.88E+01 |
| | 9 | 6.16E+01 | 1.31E+03 | 3.91E+01 |
| | 10 | 6.08E+01 | 1.20E+03 | 3.88E+01 |
| | 20 | 3.82E+01 | 4.92E+02 | 2.48E+01 |
| | 30 | 1.84E+01 | 1.98E+02 | 1.20E+01 |

Table 6.5.23 Count rate per CDL calculated for the Adipose Female phantom contaminated with I-131

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 6.73E+03 | 6.26E+01 | 5.93E+00 |
| | 1 | 8.09E+02 | 2.04E+03 | 4.62E+01 |
| | 2 | 2.77E+02 | 1.93E+03 | 2.85E+01 |
| | 3 | 1.28E+02 | 1.78E+03 | 3.79E+01 |
| | 4 | 8.36E+01 | 1.63E+03 | 4.63E+01 |
| | 5 | 7.20E+01 | 1.50E+03 | 5.24E+01 |
| | 6 | 7.00E+01 | 1.38E+03 | 5.66E+01 |
| | 7 | 7.04E+01 | 1.26E+03 | 5.92E+01 |
| | 8 | 7.08E+01 | 1.16E+03 | 6.06E+01 |
| | 9 | 7.05E+01 | 1.06E+03 | 6.09E+01 |
| | 10 | 6.96E+01 | 9.73E+02 | 6.05E+01 |
| | 20 | 4.35E+01 | 4.02E+02 | 3.86E+01 |
| | 30 | 2.10E+01 | 1.63E+02 | 1.87E+01 |

Table 6.5.24 Count rate per CDL calculated for the Post-Menopausal Adipose Female phantom contaminated with I-131

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 6.54E+03 | 6.80E+01 | 5.52E+00 |
| | 1 | 7.84E+02 | 2.31E+03 | 2.33E+01 |
| | 2 | 2.68E+02 | 2.18E+03 | 1.37E+01 |
| | 3 | 1.23E+02 | 2.01E+03 | 1.79E+01 |
| | 4 | 7.92E+01 | 1.84E+03 | 2.17E+01 |
| | 5 | 6.74E+01 | 1.69E+03 | 2.45E+01 |
| | 6 | 6.51E+01 | 1.56E+03 | 2.64E+01 |
| | 7 | 6.52E+01 | 1.43E+03 | 2.76E+01 |
| | 8 | 6.54E+01 | 1.31E+03 | 2.83E+01 |
| | 9 | 6.50E+01 | 1.20E+03 | 2.84E+01 |
| | 10 | 6.41E+01 | 1.10E+03 | 2.82E+01 |
| | 20 | 3.99E+01 | 4.54E+02 | 1.80E+01 |
| | 30 | 1.92E+01 | 1.84E+02 | 8.71E+00 |

Table 6.5.25 Count rate per CDL calculated for the Child phantom contaminated with I-131

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 4.80E+03 | 2.92E+01 | 1.06E+01 |
| | 1 | 5.89E+02 | 7.15E+02 | 1.58E+01 |
| | 2 | 2.02E+02 | 6.66E+02 | 9.42E+00 |
| | 3 | 9.57E+01 | 6.20E+02 | 1.18E+01 |
| | 4 | 6.42E+01 | 5.76E+02 | 1.40E+01 |
| | 5 | 5.58E+01 | 5.34E+02 | 1.57E+01 |
| | 6 | 5.44E+01 | 4.95E+02 | 1.69E+01 |
| | 7 | 5.45E+01 | 4.59E+02 | 1.76E+01 |
| | 8 | 5.46E+01 | 4.24E+02 | 1.79E+01 |
| | 9 | 5.43E+01 | 3.92E+02 | 1.80E+01 |
| | 10 | 5.34E+01 | 3.62E+02 | 1.78E+01 |
| | 20 | 3.31E+01 | 1.57E+02 | 1.13E+01 |
| | 30 | 1.59E+01 | 6.55E+01 | 5.45E+00 |

Table 6.5.26 Count rate per CDL calculated for the Male phantom contaminated with I-192

| | | Back Right Lung | Front Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 1.66E+04 | 1.59E+04 | 1.47E+02 | 8.29E+00 |
| | 1 | 6.50E+03 | 6.26E+03 | 8.46E+02 | 4.62E+02 |
| | 2 | 5.20E+03 | 5.02E+03 | 8.73E+02 | 4.54E+02 |
| | 3 | 4.67E+03 | 4.51E+03 | 8.65E+02 | 4.27E+02 |
| | 4 | 4.42E+03 | 4.27E+03 | 8.58E+02 | 4.12E+02 |
| | 5 | 4.27E+03 | 4.13E+03 | 8.53E+02 | 4.06E+02 |
| | 6 | 4.17E+03 | 4.03E+03 | 8.49E+02 | 4.02E+02 |
| | 7 | 4.08E+03 | 3.94E+03 | 8.45E+02 | 4.00E+02 |
| | 8 | 4.00E+03 | 3.86E+03 | 8.42E+02 | 3.98E+02 |
| | 9 | 3.92E+03 | 3.79E+03 | 8.38E+02 | 3.97E+02 |
| | 10 | 3.84E+03 | 3.72E+03 | 8.35E+02 | 3.95E+02 |
| | 20 | 3.19E+03 | 3.09E+03 | 8.09E+02 | 3.85E+02 |
| | 30 | 2.69E+03 | 2.61E+03 | 7.82E+02 | 3.73E+02 |

Table 6.5.27 Count rate per CDL calculated for the Female phantom contaminated with I-192

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 1.55E+04 | 1.51E+02 | 1.05E+01 |
| | 1 | 6.24E+03 | 8.84E+02 | 4.30E+02 |
| | 2 | 5.04E+03 | 9.12E+02 | 4.20E+02 |
| | 3 | 4.55E+03 | 9.04E+02 | 3.92E+02 |
| | 4 | 4.32E+03 | 8.97E+02 | 3.78E+02 |
| | 5 | 4.18E+03 | 8.92E+02 | 3.71E+02 |
| | 6 | 4.08E+03 | 8.87E+02 | 3.68E+02 |
| | 7 | 4.00E+03 | 8.83E+02 | 3.66E+02 |
| | 8 | 3.92E+03 | 8.80E+02 | 3.64E+02 |
| | 9 | 3.85E+03 | 8.76E+02 | 3.63E+02 |
| | 10 | 3.78E+03 | 8.73E+02 | 3.62E+02 |
| | 20 | 3.17E+03 | 8.46E+02 | 3.52E+02 |
| | 30 | 2.69E+03 | 8.18E+02 | 3.41E+02 |

Table 6.5.28 Count rate per CDL calculated for the Adipose Male phantom contaminated with I-192

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 1.07E+04 | 1.16E+02 | 3.50E+00 |
| | 1 | 4.31E+03 | 7.67E+02 | 4.12E+02 |
| | 2 | 3.48E+03 | 7.95E+02 | 4.06E+02 |
| | 3 | 3.14E+03 | 7.89E+02 | 3.82E+02 |
| | 4 | 2.98E+03 | 7.84E+02 | 3.69E+02 |
| | 5 | 2.88E+03 | 7.79E+02 | 3.63E+02 |
| | 6 | 2.82E+03 | 7.75E+02 | 3.60E+02 |
| | 7 | 2.76E+03 | 7.72E+02 | 3.58E+02 |
| | 8 | 2.70E+03 | 7.69E+02 | 3.56E+02 |
| | 9 | 2.65E+03 | 7.66E+02 | 3.55E+02 |
| | 10 | 2.60E+03 | 7.64E+02 | 3.54E+02 |
| | 20 | 2.18E+03 | 7.41E+02 | 3.45E+02 |
| | 30 | 1.85E+03 | 7.16E+02 | 3.34E+02 |

Table 6.5.29 Count rate per CDL calculated for the Adipose Female phantom contaminated with I-192

| | | 502 - Back Right Lung | 542 - Neck | 562 - Thigh |
|--------------------------------|----|------------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 1.18E+04 | 1.14E+02 | 8.11E+00 |
| | 1 | 4.76E+03 | 7.50E+02 | 5.98E+02 |
| | 2 | 3.85E+03 | 7.76E+02 | 6.08E+02 |
| | 3 | 3.48E+03 | 7.70E+02 | 5.90E+02 |
| | 4 | 3.30E+03 | 7.64E+02 | 5.79E+02 |
| | 5 | 3.20E+03 | 7.60E+02 | 5.73E+02 |
| | 6 | 3.12E+03 | 7.56E+02 | 5.70E+02 |
| | 7 | 3.06E+03 | 7.53E+02 | 5.67E+02 |
| | 8 | 3.00E+03 | 7.50E+02 | 5.65E+02 |
| | 9 | 2.94E+03 | 7.47E+02 | 5.63E+02 |
| | 10 | 2.89E+03 | 7.44E+02 | 5.61E+02 |
| | 20 | 2.42E+03 | 7.22E+02 | 5.47E+02 |
| | 30 | 2.06E+03 | 6.98E+02 | 5.30E+02 |

Table 6.5.30 Count rate per CDL calculated for the Post-Menopausal Adipose Female phantom contaminated with I-192

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 1.15E+04 | 1.28E+02 | 3.69E+00 |
| | 1 | 4.63E+03 | 8.43E+02 | 3.23E+02 |
| | 2 | 3.73E+03 | 8.74E+02 | 3.09E+02 |
| | 3 | 3.37E+03 | 8.67E+02 | 2.84E+02 |
| | 4 | 3.19E+03 | 8.61E+02 | 2.71E+02 |
| | 5 | 3.09E+03 | 8.56E+02 | 2.65E+02 |
| | 6 | 3.02E+03 | 8.52E+02 | 2.62E+02 |
| | 7 | 2.95E+03 | 8.48E+02 | 2.60E+02 |
| | 8 | 2.90E+03 | 8.45E+02 | 2.59E+02 |
| | 9 | 2.84E+03 | 8.42E+02 | 2.58E+02 |
| | 10 | 2.79E+03 | 8.39E+02 | 2.57E+02 |
| | 20 | 2.33E+03 | 8.13E+02 | 2.51E+02 |
| | 30 | 1.98E+03 | 7.86E+02 | 2.43E+02 |

Table 6.5.31 Count rate per CDL calculated for the Child phantom contaminated with I-192

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|--------------------|--------------------|
| | | cpm per CDL | cpm per CDL | cpm per CDL |
| Days following exposure | 0 | 1.45E+04 | 1.42E+02 | 1.89E+01 |
| | 1 | 5.91E+03 | 1.03E+03 | 3.58E+02 |
| | 2 | 4.78E+03 | 1.06E+03 | 3.42E+02 |
| | 3 | 4.32E+03 | 1.05E+03 | 3.14E+02 |
| | 4 | 4.10E+03 | 1.04E+03 | 3.00E+02 |
| | 5 | 3.98E+03 | 1.04E+03 | 2.94E+02 |
| | 6 | 3.88E+03 | 1.03E+03 | 2.90E+02 |
| | 7 | 3.80E+03 | 1.03E+03 | 2.89E+02 |
| | 8 | 3.73E+03 | 1.02E+03 | 2.87E+02 |
| | 9 | 3.66E+03 | 1.02E+03 | 2.86E+02 |
| | 10 | 3.59E+03 | 1.02E+03 | 2.85E+02 |
| | 20 | 3.02E+03 | 9.87E+02 | 2.77E+02 |
| | 30 | 2.57E+03 | 9.55E+02 | 2.68E+02 |

CHAPTER 7

CONCLUSIONS

The Captus 3000 Thyroid Uptake System can be used to assess the internal contamination in an individual following the use of a RDD for some isotopes. These isotopes include Co-60, Cs-137, Ir-192, and I-131. The thyroid uptake system cannot be used to detect internal contamination due to Am-241. The calculated count rate per one CDL of Am-241 is too low to differentiate it from background using this system. This is a consequence of the low dose coefficient and the low energy of the gamma-ray emission of Am-241. Even at a relatively high intake of Am-241 (1 CDL) the count rate from the thyroid uptake collimator is less than one count per minute.

In an emergency scenario, it would be more beneficial to identify the isotope than to spend time determining the BMI or body type of the individuals being scanned. The optimal position for the thyroid uptake collimator depends on the isotope inhaled. If the isotope has not been identified, the most optimal position is the back right lung followed by the neck. The thigh should not be chosen as a detection position for the thyroid uptake collimator unless circumstances prevent use of the other two locations. This is one of the consequences of a high degree of collimation. The detection efficiency is reduced as a result of a smaller angle seen by the detector, and the distance between the detector and the object of interest.

Given the threshold of one CDL, the minimum necessary counting time is one minute. This can be used as a baseline for all isotopes on the back right lung, with the exception of I-131, in which the probe would need to be placed on the neck for this counting time. In a situation

where large numbers of people are potentially contaminated, it is important to use the minimum necessary counting time to achieve efficient results.

CHAPTER 8

FUTURE WORK

Based on the conclusions from this investigation, other methods for detecting Am-241 need to be developed. Possible methods include urinalysis or fecal studies to detect low levels of this isotope. It is likely that these methodologies must retain high efficiency even a high levels of background, otherwise they will not be applicable for this application.

Another feature of the Captus 3000 Thyroid Uptake System is the Bioassay collimator, which was not fully considered in this analysis. With a considerably shorter collimator, it is possible that the bioassay collimator could be used to detect isotopes with a smaller dose coefficient (such as Am-241) following an RDD event. It would also tend to have lower decision levels, allowing it to detect smaller activities in a human.

This work focused on inhalation as the method of intake for each radionuclide. By considering ingestion, the work can be expanded to cover the two main routes of intake. This would require repeating the biokinetic analysis for ingestion and positioning the thyroid uptake collimator over the abdomen rather than the lungs or neck.

Finally, the validated model of the thyroid uptake probe could be used in conjunction with newly developed voxel phantoms. Voxel phantoms are based on digital images captured from studies completed on actual humans using Computed Tomography (CT) or Magnetic Resonance Imaging (MRI). While many of these phantoms are still undergoing development and validation, it is possible that they could provide a more realistic representation of various human body types, thus refining the simulations of internal contamination following a RDD.

APPENDIX A

THYROID UPTAKE COLLIMATOR AND SLAB PHANTOM MCNP INPUT FILE

Thyroid Uptake Collimator - 30mmPMMA, Cs-137

c Cell Cards

| | | | | |
|----|----|---------|----------------------------|------------------------------|
| 1 | 1 | -0.0012 | 1 2 3 17 19 20 -99 | imp:p=1 \$ Outside Air |
| 2 | 2 | -3.67 | -5 | imp:p=1 \$ NaI crystal |
| 3 | 4 | -1.19 | -1:-2 3 4 | imp:p=1 \$ PMMA |
| 4 | 3 | -7.82 | (-17 10):(-19 18): -20 | imp:p=1 \$ Steel |
| 5 | 5 | -1.03 | -3 2 | imp:p=1 \$ Virtual Water |
| 6 | 6 | -2.7 | 5 14 -6 | imp:p=1 \$ Aluminum |
| 7 | 7 | -1 | -4 | imp:p=1 \$ Source |
| 8 | 0 | | -9 5 | imp:p=1 \$ Vacuum |
| 9 | 1 | -0.0012 | -7 | imp:p=1 \$ Air in coll |
| 10 | 3 | -7.82 | (7 -11) | imp:p=1 \$ Inner Steel Liner |
| 11 | 8 | -11.4 | (-10 11):(-18 11 12 16 21) | imp:p=1 \$ Pb innards |
| 12 | 1 | -.0012 | -18 16 -21 | imp:p=1 \$ air in back |
| 13 | 9 | -8.4 | (-14 15):(-12 13) | imp:p=1 \$ Brass Ring |
| 14 | 1 | -0.0012 | 6 11 -15 | imp:p=1 \$ Air ret ring |
| 15 | 1 | -0.0012 | -13 6 9 14 15 | imp:p=1 \$ Air in brass tube |
| 16 | 10 | -11.4 | -16 12 | imp:p=1 \$ Pure Led sheet |
| 99 | 0 | | 99 | imp:p=0 \$ Universe |

c Surface Cards

| | | | |
|----|-----|--|------------------------------|
| 1 | rpp | 0 3.0 -30 30 -30 30 | \$ PMMA slab |
| 2 | rpp | 3.0 3.6 -30 30 -30 30 | \$ Source Holder |
| 3 | rpp | 3.6001 13.6 -30 30 -30 30 | \$ Virtual Water |
| 4 | rcc | 3.3001 -1.15 0 0 2.3 0 .2 | \$ Source |
| 5 | rcc | -21.5051 0 0 5.08 0 0 2.54 | \$ NaI Crystal |
| 6 | rcc | -21.5051 0 0 5.1308 0 0 2.824 | \$ Al Housing |
| 9 | rcc | -34.7893 0 0 13.2842 0 0 2.921 | \$ PMT Tubes space |
| 10 | trc | -11.5824 0 0 11.5824 0 0 4.445 5.3975 | \$ Outer Detector Housing ID |
| 17 | trc | -11.5824 0 0 11.5824 0 0 4.7625 5.715 | \$ Outer Detector Housing OD |
| 11 | trc | -15.7393 0 0 15.7393 0 0 2.7344 4.8018 | \$ Inner Steel Liner |
| 7 | trc | -15.7393 0 0 15.7393 0 0 2.5344 4.6018 | \$ Air in collimator |
| 12 | rcc | -40.8223 0 0 25.083 0 0 3.505 | \$ Inner Tube OD around PMT |
| 13 | rcc | -40.8223 0 0 25.083 0 0 3.175 | \$ Inner Tube ID |
| 14 | rcc | -16.3743 0 0 0.635 0 0 3.175 | \$ Retaining Ring OD |
| 15 | rcc | -16.3743 0 0 0.635 0 0 2.565 | \$ Retaining Ring ID (air) |
| 16 | rcc | -40.8223 0 0 14.9225 0 0 3.823 | \$ Detector Side Shield (Pb) |
| 18 | rcc | -40.8223 0 0 29.2399 0 0 4.445 | \$ Cyl Detector Housing ID |
| 19 | rcc | -40.8223 0 0 29.2399 0 0 4.7625 | \$ Cyl Detector Housing OD |
| 20 | rcc | -41.8223 0 0 1.0 0 0 4.7625 | \$ Back end cap |
| 21 | px | -25.8998 | \$ air plane! |
| 99 | rpp | -50 50 -50 50 -50 50 | \$ Universe |

c Data Cards

c Material Card for Air (NIST DRY AIR)

| | | |
|----|-----------|----------|
| m1 | 8016. | -0.232 |
| | 7014. | -0.755 |
| | 6012 | -1.20E-4 |
| | 18000.42c | -1.28E-2 |

c Material Card for Sodium Iodide

| | | |
|----|-----------|-----|
| m2 | 11000.04p | 0.5 |
| | 53000.04p | 0.5 |

c Material Card for grain controlled mild steel

| | | |
|----|-------|----------|
| m3 | 26054 | -0.05821 |
| | 26056 | -0.9137 |
| | 26057 | -0.0211 |
| | 26058 | -0.00281 |

```

6012      -0.0006
25055     -0.0035
15031     -0.00004
16000     -0.00005
c Material Card for PMMA
m4 6000.   0.3333
8016.     0.1333
1001.     0.5333
c Material Card for Virtual Water
m5 1001.   0.0802
6000.     0.6703
7015.     0.0214
8016.     0.1991
17000.    0.0014
20000.    0.0231
c Material Card for Aluminum
m6 13027.  1
c Material Card for polyester (sources)
m7 6000.   0.333
1001.     0.533
8016.     0.133
c Material Card for Antimonial Lead
m8 82000 0.96
51000 0.04
c Material Card for High Brass
m9 29000 0.65
30000 0.35
c Material Card for Pure Lead
m10 82000 1
mode p
phys:p 4j 1
sdef par=2 rad=d1 ext=d2 pos=3.3 0 0 axs=0 1 0 vec=0 0 1 erg=d3
si1 0 0.2
sp1 -21 1
si2 -1.15 1.15
sp2 -21 0
si3 1 0.661645
sp3 .897759
c Two Tallies
f8:p 2 $ volume of crystal
f18:p 2 $ same volume
c energy bins
e0 0 1e-8 0.005 1024i 2.046
c Gaussian Energy Broadening
ft8 GEB -0.00298579 0.0925102 -0.4
print
nps 1E8

```

APPENDIX B

SLAB PHANTOM SPECTRAL DATA




Figure B.1 Measured and calculated spectra for Am-241 with 0 mm PMMA




Figure B.2 Measured and calculated spectra for Am-241 with 60 mm PMMA




Figure B.3 Measured and calculated spectra for Am-241 with 108 mm PMMA




Figure B.4 Measured and calculated spectra for Ba-133 with 0 mm PMMA




Figure B.5 Measured and calculated spectra for Ba-133 with 60 mm PMMA




Figure B.6 Measured and calculated spectra for Ba-133 with 108 mm PMMA




Figure B.7 Measured and calculated spectra for Co-60 with 0 mm PMMA




Figure B.8 Measured and calculated spectra for Co-60 with 60 mm PMMA




Figure B.9 Measured and calculated spectra for Co-60 with 108 mm PMMA




Figure B.10 Measured and calculated spectra for Cs-137 with 0 mm PMMA




Figure B.11 Measured and calculated spectra for Cs-137 with 60 mm PMMA




Figure B.12 Measured and calculated spectra for Cs-137 with 108 mm PMMA




Figure B.13 Measured and calculated spectra for Mn-54 with 0 mm PMMA




Figure B.14 Measured and calculated spectra for Mn-54 with 60 mm PMMA




Figure B.15 Measured and calculated spectra for Mn-54 with 108 mm PMMA




Figure B.16 Measured and calculated spectra for Na-22 with 0 mm PMMA




Figure B.17 Measured and calculated spectra for Na-22 with 60 mm PMMA




Figure B.18 Measured and calculated spectra for Na-22 with 108 mm PMMA

APPENDIX C

CONDENSED MIRD PHANTOM MCNP INPUT FILE

Male Phantom contaminated with Cs-137

| | | | | |
|----|---|-----------|--|---------------------------------|
| 1 | 1 | -0.001293 | -1 (607:-37:606) (-606:601:35) (600:-35) & (-615:37:-43:44:4:-616) (37:-608:609) & (37:-608:610) 900 901 902 903 | |
| 2 | 2 | -0.2958 | ((-2 -4 3):(-2 4)) 5 | \$ left lung |
| 3 | 3 | -0.9869 | -7 51 -6 (-8:32) 84 101 #2 #24 #28 #58 #59 (113:115) (114:115) #62 #700 | \$ torso insd ribs/lvrtop-shldr |
| 4 | 3 | -0.9869 | -7 8 -32 117 113 114 #15 #16 #17 #18 #19 #20 #700 (-4:-9:116:118:-119) (-4:-9:116:120:-121) | \$torso |
| 5 | 3 | -0.9869 | -7 8 -117 51 113 114 #9 #13 #14 #700 | \$ torso |
| 6 | 3 | -0.9869 | -7 50 -51 56 84 96 105 106 113 114 #10 #11 #12 #27 #32 #43 #44 #47 #700 | \$ torso |
| 7 | 3 | -0.9869 | -7 97 -50 (83:-86:87:-88) 113 114 #30 #33 #38 #39 #63 #64 #65 #700 | \$ torso abdoman |
| 8 | 3 | -0.9869 | -7 37 -97 95 113 114 #31 #33 #38 #65 #66 #700 | \$ torso abdoman |
| 9 | 4 | -1.4862 | 8 -9 5 -10 | \$ rib |
| 10 | 4 | -1.4862 | 8 -9 11 -12 | \$ rib |
| 11 | 4 | -1.4862 | 8 -9 13 -14 | \$ rib |
| 12 | 4 | -1.4862 | 8 -9 15 -16 | \$ rib |
| 13 | 4 | -1.4862 | 8 -9 17 -18 | \$ rib |
| 14 | 4 | -1.4862 | 8 -9 19 -20 | \$ rib |
| 15 | 4 | -1.4862 | 8 -9 21 -22 | \$ rib |
| 16 | 4 | -1.4862 | 8 -9 23 -24 | \$ rib |
| 17 | 4 | -1.4862 | 8 -9 25 -26 | \$ rib |
| 18 | 4 | -1.4862 | 8 -9 27 -28 | \$ rib |
| 19 | 4 | -1.4862 | 8 -9 29 -30 | \$ rib |
| 20 | 4 | -1.4862 | 8 -9 31 -32 | \$ rib |
| 21 | 3 | -0.9869 | ((35 -34):(-33 6 -35)) 102 (84:85) #37 #60 #61 #62 #700 | \$ head |
| 22 | 3 | -0.9869 | -37 38 -39 103 #700 | \$ left leg |
| 23 | 3 | -0.9869 | -37 38 -40 104 #22 #700 | \$ right leg |
| 24 | 2 | -0.2958 | ((-41 -4 42):(-41 4)) 5 | \$ right lung |
| 25 | 3 | -0.9869 | 715 -37 43 -44 -4 716 39 40 72 73 #700 #600 | \$ genitalia |
| 26 | 3 | -0.9869 | -47 | \$ brain |
| 27 | 3 | -0.9869 | 50 -51 -48 -49 #10 #11 #12 | \$ liver |
| 28 | 3 | -0.9869 | (-52 54):(-53 -54 55) | \$ heart |
| 29 | 3 | -0.9869 | -56 | \$ stomach |
| 30 | 3 | -0.9869 | 138 -57 58 -59 | \$ Ascending Colon Wall |
| 31 | 3 | -0.9869 | (-63 141 65 -61):(-64 142 37 -65) | \$ Sigmoid Colon Wall |
| 32 | 3 | -0.9869 | -62 139 66 -67 59 | \$ Transverse Colon Wall |
| 33 | 3 | -0.9869 | -60 140 61 -59 -83 | \$ Descending Colon Wall |
| 35 | 3 | -0.9869 | -72 | \$ testicle |
| 36 | 3 | -0.9869 | -73 | \$ testicle |
| 37 | 3 | -0.9869 | -74 75 -76 6 -77 | \$ thyroid |
| 38 | 4 | -1.4862 | -82 83 37 -78 80 (79:-81) | \$ pelvis |
| 39 | 4 | -1.4862 | -84 78 -85 102 | \$ spine |
| 40 | 3 | -0.9869 | -83 86 -50 88 -87 #30 #32 #33 #63 #64 #65 | \$ small int. |
| 41 | 1 | -0.001293 | -107 606 -4 | \$ air |
| 42 | 1 | -0.001293 | -108 606 -4 | \$ air |
| 43 | 3 | -0.9869 | -92 65 | \$ kidney |
| 44 | 3 | -0.9869 | -93 -94 | \$ kidney |
| 45 | 3 | -0.9869 | -95 | \$ bladder |
| 46 | 3 | -0.9869 | -96 | \$ spleen |
| 47 | 3 | -0.9869 | -98 99 (-65:100) | \$ pancreas |
| 48 | 3 | -0.9869 | -101 | \$ thymus |
| 49 | 4 | -1.4862 | 47 -102 #60 #61 | \$ skull |

| | | | | |
|-----------------------|-----|----------|---|-----------------------------|
| 50 | 4 | -1.4862 | -103 38 -37 | \$ leg bone |
| 51 | 4 | -1.4862 | -104 38 -37 | \$ leg bone |
| 52 | 3 | -0.9869 | -105 92 | \$ adrenal |
| 53 | 3 | -0.9869 | -106 93 | \$ adrenal |
| 54 | 4 | -1.4862 | 37 -115 -113 | \$ arm bone |
| 55 | 4 | -1.4862 | 37 -115 -114 | \$ arm bone |
| 56 | 4 | -1.4862 | 4 9 -32 -116 117 -118 119 | \$ scapulae |
| 57 | 4 | -1.4862 | 4 9 -32 -116 117 -120 121 | \$ scapulae |
| 58 | 4 | -1.4862 | -4 -122 -123 124 | \$ clavicle |
| 59 | 4 | -1.4862 | -4 -122 -125 126 | \$ clavicle |
| 60 | 3 | -0.9869 | -33 128 129 -130 133 -134 -4 #700 | \$ eye lense |
| 61 | 3 | -0.9869 | -33 128 -131 132 133 -134 -4 #700 | \$ eye lense |
| 62 | 3 | -0.9869 | -77 -137 51 | \$ oesophagus |
| 63 | 3 | -0.9869 | -138 58 -59 | \$ Ascending Colon Interior |
| 64 | 3 | -0.9869 | -139 66 -67 | \$ Transvers Colon Interior |
| 65 | 3 | -0.9869 | -140 61 -59 -83 | \$ Decending Colon Interior |
| 66 | 3 | -0.9869 | (-141 65 -61) : (-142 37 -65) | \$ Sigmoid Colon Interior |
| 600 | 0 | | -600 35 34 902 : -601 33 -35 606 902 : & | \$ Head & Neck |
| | | | -606 6 33 -607 902: -607 7 -6 37 900 901 902 : & | \$ Shoulders & Torso |
| | | | (((-46 616)(43 -44)(615 -37)):(615 -45)(610 609)(46 -4)(43 -44))) : & | \$ Genitalia |
| | | | -610 40 -37 38 : -609 39 -37 38 903: & | \$ Legs |
| | | | -708 608 -609 : -708 608 -610 : & | \$ Feet |
| | | | -38 708 -610 40 : -38 708 -609 39 | |
| 700 | 5 | -1.04 | 700 35 102 -34 : 701 -33 -35 6 : & | \$ Head & Neck |
| | | | 706 -6 701 -707 : 707 -7 -6 37 114 113 : & | \$ Shoulders & Torso |
| | | | (((-46 -716)(43 -44)(609 610)(715 -37)):(-715 45)(610 609)(46 -4)(43 -44))) : & | \$ Genitalia |
| | | | -40 710 -37 38 : -39 709 -37 38 : & | \$ Legs |
| | | | -38 708 -39 : -38 708 -40 | \$ Feet |
| 900 | 1 | -.001293 | -900 7 515 514 505 504 | |
| 901 | 1 | -.001293 | -901 7 535 534 525 524 | |
| 902 | 1 | -.001293 | -902 6 33 34 555 554 545 544 | |
| 903 | 1 | -.001293 | -903 39 575 574 565 564 | |
| c Detector in box 900 | | | | |
| 502 | 502 | -3.67 | -501 | \$ NaI crystal |
| 503 | 503 | -7.82 | (-505 504):(-514 513): -515 | \$ Steel |
| 504 | 506 | -2.7 | 501 510 -502 | \$ Aluminum |
| 505 | 501 | -0.00012 | -503 | \$ Vacuum |
| 506 | 501 | -0.0012 | -507 | \$ Air in coll |
| 507 | 503 | -7.82 | (507 -506) | \$ Inner St Liner |
| 508 | 508 | -11.4 | (-504 506):(-513 506 508 512 516) | \$ Pb innards |
| 509 | 501 | -0.0012 | -513 512 -516 | \$ air in back |
| 510 | 509 | -8.4 | (-510 511):(-508 509) | \$ Brass Ring |
| 511 | 501 | -0.0012 | 502 506 -511 | \$ Air ret ring |
| 512 | 501 | -0.0012 | -509 502 503 510 511 | \$ Air in brs tube |
| 513 | 510 | -11.4 | -512 508 | \$ Pure Led sheet |
| c Detector in box 901 | | | | |
| 522 | 502 | -3.67 | -521 | \$ NaI crystal |
| 523 | 503 | -7.82 | (-525 524):(-534 533): -535 | \$ Steel |
| 524 | 506 | -2.7 | 521 530 -522 | \$ Aluminum |
| 525 | 501 | -0.00012 | -523 | \$ Vacuum |
| 526 | 501 | -0.0012 | -527 | \$ Air in coll |
| 527 | 503 | -7.82 | (527 -526) | \$ Inner St Liner |
| 528 | 508 | -11.4 | (-524 526):(-533 526 528 532 536) | \$ Pb innards |
| 529 | 501 | -0.0012 | -533 532 -536 | \$ air in back |
| 530 | 509 | -8.4 | (-530 531):(-528 529) | \$ Brass Ring |
| 531 | 501 | -0.0012 | 522 526 -531 | \$ Air ret ring |

532 501 -0.0012 -529 522 523 530 531 \$ Air in brs tube
 533 510 -11.4 -532 528 \$ Pure Led sheet
 c Detector in box 902
 542 502 -3.67 -541 \$ NaI crystal
 543 503 -7.82 (-545 544):(-554 553): -555 \$ Steel
 544 506 -2.7 541 550 -542 \$ Aluminum
 545 501 -0.00012 -543 \$ Vacuum
 546 501 -0.0012 -547 \$ Air in coll
 547 503 -7.82 (547 -546) \$ Inner St Liner
 548 508 -11.4 (-544 546):(-553 546 548 552 556) \$ Pb innards
 549 501 -.0012 -553 552 -556 \$ air in back
 550 509 -8.4 (-550 551):(-548 549) \$ Brass Ring
 551 501 -0.0012 542 546 -551 \$ Air ret ring
 552 501 -0.0012 -549 542 543 550 551 \$ Air in brs tube
 553 510 -11.4 -552 548 \$ Pure Led sheet
 c Detector in box 903
 562 502 -3.67 -561 \$ NaI crystal
 563 503 -7.82 (-565 564):(-574 573): -575 \$ Steel
 564 506 -2.7 561 570 -562 \$ Aluminum
 565 501 -0.00012 -563 \$ Vacuum
 566 501 -0.0012 -567 \$ Air in coll
 567 503 -7.82 (567 -566) \$ Inner St Liner
 568 508 -11.4 (-564 566):(-573 566 568 572 576) \$ Pb innards
 569 501 -.0012 -573 572 -576 \$ air in back
 570 509 -8.4 (-570 571):(-568 569) \$ Brass Ring
 571 501 -0.0012 562 566 -571 \$ Air ret ring
 572 501 -0.0012 -569 562 563 570 571 \$ Air in brs tube
 573 510 -11.4 -572 568 \$ Pure Led sheet
 67 0 1

 SURFACES

C 2 concentric elliptical cylinders and planes to define eye lenses
 127 SQ 100 64 0 0 0 0 -6400 0 0 0
 128 SQ 88.36 40.96 0 0 0 0 -3619.2256 0 0 0
 129 PX 2
 130 PX 4
 131 PX -2
 132 PX -4
 133 PZ 82.5
 134 PZ 84.5
 C segmenting planes for RBM regions in leg and arm bones
 135 PZ -22.8
 136 PZ 52.6
 C Oesophagus
 137 SQ 0.16 1.0 0 0 0 0 -0.16 0.5 2.5 0 \$ Oesophagus Exterior
 C Colon Wall
 138 SQ 1 1 0 0 0 0 -3.209 -8.5 -2.36 0 \$ Ascending Colon Interior
 139 SQ 0 0.9467 3.8927 0 0 0 -3.6854 0 -2.36 25.5
 140 GQ 1.796 2.496 0.0674 0 0.818 -0.066 -30.75 -7.12 -0.602 132.2
 141 TY 3 0 8.72 5.72 0.91 0.91 \$ Upper Sigmoid Interior
 142 TY 3 0 0 3 0.91 0.91 \$ Lower Sigmoid Interior
 C Boxes for Detectors
 900 900 BOX 0.39 10.9607 38.36 -17.78 0 0 &


```

0 50.8 0 0 0 17.78
901 901 BOX 0.39 -10.9609 38.35 -17.78 0 0 &
0 -50.8 0 0 0 17.80
902 BOX -8.89 -10 70.01 17.78 0 0 0 -50.8 0 0 0 17.78
903 903 BOX 19.98 -8.89 0 50.8 0 0 0 17.78 0 0 0 -17.78
c
c c
c Detector in Box 900
501 501 rcc -21.5051 0 0 5.08 0 0 2.54 $ NaI Crystal
502 501 rcc -21.5051 0 0 5.1308 0 0 2.824 $ Al Housing
503 501 rcc -34.7893 0 0 13.2842 0 0 2.921 $ PMT Tubes space
504 501 trc -11.5824 0 0 11.5824 0 0 4.445 5.3975 $ Outer Detector Housing ID
505 501 trc -11.5824 0 0 11.5824 0 0 4.7625 5.715 $ Outer Detector Housing OD
506 501 trc -15.7393 0 0 15.7393 0 0 2.7344 4.8018 $ Inner Steel Liner
507 501 trc -15.7393 0 0 15.7393 0 0 2.5344 4.6018 $ Air in collimator
508 501 rcc -40.8223 0 0 25.083 0 0 3.505 $ Inner Tube OD around PMT
509 501 rcc -40.8223 0 0 25.083 0 0 3.175 $ Inner Tube ID
510 501 rcc -16.3743 0 0 0.635 0 0 3.175 $ Retaining Ring OD
511 501 rcc -16.3743 0 0 0.635 0 0 2.565 $ Retaining Ring ID (air)
512 501 rcc -40.8223 0 0 14.9225 0 0 3.823 $ Detector Side Shield (Pb)
513 501 rcc -40.8223 0 0 29.2399 0 0 4.445 $ Cyl Detector Housing ID
514 501 rcc -40.8223 0 0 29.2399 0 0 4.7625 $ Cyl Detector Housing OD
515 501 rcc -41.8223 0 0 1.0 0 0 4.7625 $ Back end cap
516 501 px -25.8998 $ air plane!
c Detector in Box 901
521 502 rcc -21.5051 0 0 5.08 0 0 2.54 $ NaI Crystal
522 502 rcc -21.5051 0 0 5.1308 0 0 2.824 $ Al Housing
523 502 rcc -34.7893 0 0 13.2842 0 0 2.921 $ PMT Tubes space
524 502 trc -11.5824 0 0 11.5824 0 0 4.445 5.3975 $ Outer Detector Housing ID
525 502 trc -11.5824 0 0 11.5824 0 0 4.7625 5.715 $ Outer Detector Housing OD
526 502 trc -15.7393 0 0 15.7393 0 0 2.7344 4.8018 $ Inner Steel Liner
527 502 trc -15.7393 0 0 15.7393 0 0 2.5344 4.6018 $ Air in collimator
528 502 rcc -40.8223 0 0 25.083 0 0 3.505 $ Inner Tube OD around PMT
529 502 rcc -40.8223 0 0 25.083 0 0 3.175 $ Inner Tube ID
530 502 rcc -16.3743 0 0 0.635 0 0 3.175 $ Retaining Ring OD
531 502 rcc -16.3743 0 0 0.635 0 0 2.565 $ Retaining Ring ID (air)
532 502 rcc -40.8223 0 0 14.9225 0 0 3.823 $ Detector Side Shield (Pb)
533 502 rcc -40.8223 0 0 29.2399 0 0 4.445 $ Cyl Detector Housing ID
534 502 rcc -40.8223 0 0 29.2399 0 0 4.7625 $ Cyl Detector Housing OD
535 502 rcc -41.8223 0 0 1.0 0 0 4.7625 $ Back end cap
536 502 px -25.8998 $ air plane!
c Detector in Box 902
541 503 rcc -21.5051 0 0 5.08 0 0 2.54 $ NaI Crystal
542 503 rcc -21.5051 0 0 5.1308 0 0 2.824 $ Al Housing
543 503 rcc -34.7893 0 0 13.2842 0 0 2.921 $ PMT Tubes space
544 503 trc -11.5824 0 0 11.5824 0 0 4.445 5.3975 $ Outer Detector Housing ID
545 503 trc -11.5824 0 0 11.5824 0 0 4.7625 5.715 $ Outer Detector Housing OD
546 503 trc -15.7393 0 0 15.7393 0 0 2.7344 4.8018 $ Inner Steel Liner
547 503 trc -15.7393 0 0 15.7393 0 0 2.5344 4.6018 $ Air in collimator
548 503 rcc -40.8223 0 0 25.083 0 0 3.505 $ Inner Tube OD around PMT
549 503 rcc -40.8223 0 0 25.083 0 0 3.175 $ Inner Tube ID
550 503 rcc -16.3743 0 0 0.635 0 0 3.175 $ Retaining Ring OD
551 503 rcc -16.3743 0 0 0.635 0 0 2.565 $ Retaining Ring ID (air)
552 503 rcc -40.8223 0 0 14.9225 0 0 3.823 $ Detector Side Shield (Pb)
553 503 rcc -40.8223 0 0 29.2399 0 0 4.445 $ Cyl Detector Housing ID
554 503 rcc -40.8223 0 0 29.2399 0 0 4.7625 $ Cyl Detector Housing OD

```

```

555 503 rcc -41.8223 0 0 1.0 0 0 4.7625 $ Back end cap
556 503 px -25.8998 $ air plane!
c Detector in Box 903
561 504 rcc -21.5051 0 0 5.08 0 0 2.54 $ NaI Crystal
562 504 rcc -21.5051 0 0 5.1308 0 0 2.824 $ Al Housing
563 504 rcc -34.7893 0 0 13.2842 0 0 2.921 $ PMT Tubes space
564 504 trc -11.5824 0 0 11.5824 0 0 4.445 5.3975 $ Outer Detector Housing ID
565 504 trc -11.5824 0 0 11.5824 0 0 4.7625 5.715 $ Outer Detector Housing OD
566 504 trc -15.7393 0 0 15.7393 0 0 2.7344 4.8018 $ Inner Steel Liner
567 504 trc -15.7393 0 0 15.7393 0 0 2.5344 4.6018 $ Air in collimator
568 504 rcc -40.8223 0 0 25.083 0 0 3.505 $ Inner Tube OD around PMT
569 504 rcc -40.8223 0 0 25.083 0 0 3.175 $ Inner Tube ID
570 504 rcc -16.3743 0 0 0.635 0 0 3.175 $ Retaining Ring OD
571 504 rcc -16.3743 0 0 0.635 0 0 2.565 $ Retaining Ring ID (air)
572 504 rcc -40.8223 0 0 14.9225 0 0 3.823 $ Detector Side Shield (Pb)
573 504 rcc -40.8223 0 0 29.2399 0 0 4.445 $ Cyl Detector Housing ID
574 504 rcc -40.8223 0 0 29.2399 0 0 4.7625 $ Cyl Detector Housing OD
575 504 rcc -41.8223 0 0 1.0 0 0 4.7625 $ Back end cap
576 504 px -25.8998 $ air plane!

```

C Data Cards

TRANSFORMATIONS

IMP:P 1 118R 0

C

C Sources

SDEF PAR=2 ERG=D1 CEL=D2 RAD=fcel=D3 &
 POS=fcel=D4 EXT=fcel=D5 AXS=fcel=D6

SI1 L 0.662 0.0332 0.0318

SP1 0.898 0.0392 0.0213

C Left Lung, Right Lung, Stomach, Small Int., Heart, Ascending Colon,

C Sigmoid Colon, Transvers Colon, Descending Colon, Bladder,

C Body Tissue (3, 4, 5, 6, 7, 8, 21, 22, 23, 25)

SI2 L 2 24 29 40 28 30 31 32 33 45 3 4 5 6 7 8 21 22 23 25

SP2 D 1

DS3 S 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

DS4 L 8.5 0 43.4 -8.5 0 43.4 8 -4 35 0 -3.8 11.3 -1 -3 51 &

-8.5 -2.36 14.35 5 0 -0.1 -10.6 -2.36 25.5 8.72 0 8.52 &

0 -4.5 8 0 0 42.9 0 0 50.8 0 0 42.9 0 0 26.9 &

0 0 11.9 0 0 -0.1 0 0 69.9 10.5 0 -80.1 -10.5 0 -80.1 &

0 -8 -4.9

DS5 S 30 31 0 32 0 33 34 35 36 0 37 38 39 40 41 42 43 44 45 46

DS6 L 0 0 1 0 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 1 &

1 0 0 0 0 1 0 0 0 0 0 1 0 0 1 0 0 1 &

0 0 1 0 0 1 0 0 1 0 0 1 0 0 1

SI7 0 7.6

SP7 -21 1

SI8 0 7.6

SP8 -21 1

SI9 0 8.2

SP9 -21 2

SI10 0 11.4

SP10 -21 1

SI11 0 8.2

SP11 -21 2
SI12 0 2.6
SP12 -21 1
SI13 0 7.1
SP13 -21 1
SI14 0 3.85
SP14 -21 1
SI15 0 4
SP15 -21 1
SI16 0 5.2
SP16 -21 2
SI17 0 20.2
SP17 -21 1
SI18 0 20.3
SP18 -21 1
SI19 0 20.3
SP19 -21 1
SI20 0 20.3
SP20 -21 1
SI21 0 20.3
SP21 -21 1
SI22 0 20.3
SP22 -21 1
SI23 0 10.1
SP23 -21 1
SI24 0 11
SP24 -21 1
SI25 0 11
SP25 -21 1
SI26 0 8.1
SP26 -21 1
SI27 0 16.6
SP27 -21 1
SI30 0 24.6
SP30 -21 0
SI31 0 24.6
SP31 -21 0
SI32 0 10.2
SP32 -21 0
SI33 0 9.75
SP33 -21 0
SI34 0 8.92
SP34 -21 0
SI35 0 21.2
SP35 -21 0
SI36 0 16
SP36 -21 0
SI37 0 27.2
SP37 -21 0
SI38 0 16.6
SP38 -21 0
SI39 0 8.1
SP39 -21 0
SI40 0 16.2
SP40 -21 0
SI41 0 15.2

SP41 -21 0
 SI42 0 12.2
 SP42 -21 0
 SI43 0 24.2
 SP43 -21 0
 SI44 0 80.2
 SP44 -21 0
 SI45 0 80.2
 SP45 -21 0
 SI46 0 5
 SP46 -21 0
 C
 C Tally Cards
 c Back Right Lung
 F8:P 502
 E8 0 1e-8 0.005 1024i 2.046
 FT8 SCX 2 GEB -0.00298579 0.0925102 -0.4
 c Front Right Lung
 F18:P 522
 E18 0 1e-8 0.005 1024i 2.046
 FT18 SCX 2 GEB -0.00298579 0.0925102 -0.4
 c Front Neck Under Chin
 F28:P 542
 E28 0 1e-8 0.005 1024i 2.046
 FT28 SCX 2 GEB -0.00298579 0.0925102 -0.4
 c Outer Left Leg
 F38:P 562
 E38 0 1e-8 0.005 1024i 2.046
 FT38 SCX 2 GEB -0.00298579 0.0925102 -0.4
 C
 C Material Cards
 C THIS IS THE COMPOSITION FOR AIR
 M1 7014 -.7558 8016 -.2314 18000 -.0128
 C THIS IS THE COMPOSITION FOR LUNG TISSUE
 M2 1001 -.1021
 6012 -.1001
 7014 -.0280
 8016 -.7596
 11023 -.0019
 15031 -.0008
 16032 -.0023
 17000 -.0027
 19000 -.0020
 20000 -.0001
 26000 -.0004
 C THE COMPOSITION FOR TOTAL BODY MINUS SKELETON AND LUNGS
 M3 1001 -.1047
 6012 -.2302
 7014 -.0234
 8016 -.6321
 11023 -.0013
 12000 -.0002
 15031 -.0024
 16032 -.0022
 17000 -.0014
 19000 -.0021

C THE COMPOSITION FOR SKELETAL TISSUE

M4 1001 -.0704

6012 -.2279

8016 -.4856

7014 -.0387

11023 -.0032

12000 -.0011

15031 -.0694

16032 -.0017

17000 -.0014

19000 -.0015

20000 -.0991

c Adult Tissues (Density = 1.04 g/cc)

M5 1001 -0.10454

6012 -0.22663

7014 -0.02490

8016 -0.63525

11023 -0.00112

12000 -0.00013

14000 -0.00030

15031 -0.00134

16032 -0.00204

17000 -0.00133

19000 -0.00208

20000 -0.00024

26000 -0.00005

30000 -0.00003

37085 -0.000007217

37087 -0.000002783

40000 -0.00001

c Detectors Materials

c Material Card for Air (NIST DRY AIR)

m501 8016. -0.232

7014. -0.755

6012 -1.20E-4

18000.42c -1.28E-2

c Material Card for Sodium Iodide

m502 11000.04p 0.5

53000.04p 0.5

c Material Card for grain controlled mild steel

m503 26054 -0.05821

26056 -0.9137

26057 -0.0211

26058 -0.00281

6012 -0.0006

25055 -0.0035

15031 -0.00004

16000 -0.00005

c Material Card for Aluminum

m506 13027. 1

c Material Card for Antimonial Lead

m508 82000 0.96

51000 0.04

c Material Card for High Brass

m509 29000 0.65

30000 0.35

```
c Material Card for Pure Lead
m510 82000 1
lost 50
c STOP NPS 1E8 F38 0.01
NPS 4E9
RAND GEN=2 SEED=1561615651
PHYS:P 4J 1
PRINT
MODE P
```

APPENDIX D

MIRD PHANTOM RESULTS FOR Cs-137, Co-60, Am-241, I-131, Ir-192

Table D.1 Count rate per Bq calculated for the Male phantom contaminated with Cs-137

| | | Back Right Lung | Front Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 1.85E-04 | 1.77E-04 | 1.51E-05 | 1.31E-06 |
| | 1 | 4.29E-04 | 4.63E-04 | 5.07E-04 | 2.47E-04 |
| | 2 | 4.11E-04 | 4.48E-04 | 5.20E-04 | 2.54E-04 |
| | 3 | 3.94E-04 | 4.30E-04 | 5.08E-04 | 2.49E-04 |
| | 4 | 3.83E-04 | 4.19E-04 | 4.99E-04 | 2.44E-04 |
| | 5 | 3.76E-04 | 4.11E-04 | 4.91E-04 | 2.40E-04 |
| | 6 | 3.71E-04 | 4.05E-04 | 4.84E-04 | 2.37E-04 |
| | 7 | 3.66E-04 | 4.00E-04 | 4.79E-04 | 2.35E-04 |
| | 8 | 3.63E-04 | 3.97E-04 | 4.74E-04 | 2.32E-04 |
| | 9 | 3.60E-04 | 3.93E-04 | 4.70E-04 | 2.30E-04 |
| | 10 | 3.57E-04 | 3.90E-04 | 4.66E-04 | 2.28E-04 |
| | 20 | 3.33E-04 | 3.64E-04 | 4.36E-04 | 2.13E-04 |
| | 30 | 3.13E-04 | 3.42E-04 | 4.09E-04 | 2.00E-04 |

Table D.2 Count rate per Bq calculated for the Female phantom contaminated with Cs-137

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 1.73E-04 | 1.49E-05 | 1.59E-06 |
| | 1 | 5.41E-04 | 6.39E-04 | 2.37E-04 |
| | 2 | 5.29E-04 | 6.56E-04 | 2.43E-04 |
| | 3 | 5.09E-04 | 6.42E-04 | 2.39E-04 |
| | 4 | 4.97E-04 | 6.30E-04 | 2.34E-04 |
| | 5 | 4.88E-04 | 6.20E-04 | 2.30E-04 |
| | 6 | 4.81E-04 | 6.12E-04 | 2.27E-04 |
| | 7 | 4.76E-04 | 6.05E-04 | 2.25E-04 |
| | 8 | 4.71E-04 | 5.99E-04 | 2.23E-04 |
| | 9 | 4.67E-04 | 5.94E-04 | 2.21E-04 |
| | 10 | 4.63E-04 | 5.89E-04 | 2.19E-04 |
| | 20 | 4.33E-04 | 5.50E-04 | 2.05E-04 |
| | 30 | 4.06E-04 | 5.16E-04 | 1.92E-04 |

Table D.3 Count rate per Bq calculated for the Adipose Male phantom contaminated with Cs-137

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 1.22E-04 | 1.03E-05 | 6.41E-07 |
| | 1 | 3.67E-04 | 5.80E-04 | 2.29E-04 |
| | 2 | 3.58E-04 | 5.96E-04 | 2.36E-04 |
| | 3 | 3.45E-04 | 5.84E-04 | 2.31E-04 |
| | 4 | 3.36E-04 | 5.73E-04 | 2.27E-04 |
| | 5 | 3.30E-04 | 5.64E-04 | 2.23E-04 |
| | 6 | 3.26E-04 | 5.56E-04 | 2.20E-04 |
| | 7 | 3.22E-04 | 5.50E-04 | 2.18E-04 |
| | 8 | 3.19E-04 | 5.45E-04 | 2.16E-04 |
| | 9 | 3.16E-04 | 5.40E-04 | 2.14E-04 |
| | 10 | 3.14E-04 | 5.36E-04 | 2.12E-04 |
| | 20 | 2.93E-04 | 5.01E-04 | 1.98E-04 |
| | 30 | 2.75E-04 | 4.70E-04 | 1.86E-04 |

Table D.4 Count rate per Bq calculated for the Adipose Female phantom contaminated with Cs-137

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 1.29E-04 | 1.14E-05 | 9.44E-07 |
| | 1 | 4.21E-04 | 5.63E-04 | 3.30E-04 |
| | 2 | 4.12E-04 | 5.78E-04 | 3.40E-04 |
| | 3 | 3.97E-04 | 5.66E-04 | 3.33E-04 |
| | 4 | 3.88E-04 | 5.55E-04 | 3.27E-04 |
| | 5 | 3.81E-04 | 5.46E-04 | 3.21E-04 |
| | 6 | 3.76E-04 | 5.39E-04 | 3.17E-04 |
| | 7 | 3.71E-04 | 5.33E-04 | 3.14E-04 |
| | 8 | 3.68E-04 | 5.28E-04 | 3.11E-04 |
| | 9 | 3.64E-04 | 5.23E-04 | 3.08E-04 |
| | 10 | 3.62E-04 | 5.19E-04 | 3.06E-04 |
| | 20 | 3.38E-04 | 4.85E-04 | 2.86E-04 |
| | 30 | 3.17E-04 | 4.55E-04 | 2.68E-04 |

Table D.5 Count rate per Bq calculated for the Post-Menopausal Adipose Female phantom contaminated with Cs-137

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 2.09E-05 | 7.59E-06 | 8.40E-07 |
| | 1 | 1.10E-04 | 1.55E-04 | 5.54E-05 |
| | 2 | 1.10E-04 | 1.58E-04 | 5.68E-05 |
| | 3 | 1.06E-04 | 1.55E-04 | 5.57E-05 |
| | 4 | 1.04E-04 | 1.52E-04 | 5.46E-05 |
| | 5 | 1.02E-04 | 1.49E-04 | 5.37E-05 |
| | 6 | 1.01E-04 | 1.48E-04 | 5.31E-05 |
| | 7 | 9.98E-05 | 1.46E-04 | 5.25E-05 |
| | 8 | 9.89E-05 | 1.44E-04 | 5.20E-05 |
| | 9 | 9.80E-05 | 1.43E-04 | 5.15E-05 |
| | 10 | 9.72E-05 | 1.42E-04 | 5.11E-05 |
| | 20 | 9.08E-05 | 1.33E-04 | 4.77E-05 |
| | 30 | 8.52E-05 | 1.25E-04 | 4.48E-05 |

Table D.6 Count rate per Bq calculated for the Child phantom contaminated with Cs-137

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 2.28E-04 | 1.90E-05 | 0.00E+00 |
| | 1 | 7.00E-04 | 7.43E-04 | 3.86E-04 |
| | 2 | 6.82E-04 | 7.62E-04 | 3.98E-04 |
| | 3 | 6.57E-04 | 7.45E-04 | 3.90E-04 |
| | 4 | 6.41E-04 | 7.31E-04 | 3.83E-04 |
| | 5 | 6.29E-04 | 7.20E-04 | 3.77E-04 |
| | 6 | 6.21E-04 | 7.10E-04 | 3.72E-04 |
| | 7 | 6.13E-04 | 7.03E-04 | 3.68E-04 |
| | 8 | 6.07E-04 | 6.96E-04 | 3.64E-04 |
| | 9 | 6.02E-04 | 6.90E-04 | 3.61E-04 |
| | 10 | 5.97E-04 | 6.84E-04 | 3.58E-04 |
| | 20 | 5.58E-04 | 6.39E-04 | 3.35E-04 |
| | 30 | 5.24E-04 | 6.00E-04 | 3.14E-04 |

Table D.7 Count Rate per Bq calculated for the Male phantom contaminated with Co-60

| | | Back Right Lung | Front Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 2.76E-04 | 2.65E-04 | 6.39E-05 | 6.55E-06 |
| | 1 | 1.30E-04 | 1.33E-04 | 5.24E-05 | 2.04E-05 |
| | 2 | 1.06E-04 | 1.08E-04 | 4.85E-05 | 2.02E-05 |
| | 3 | 9.57E-05 | 9.63E-05 | 4.53E-05 | 1.83E-05 |
| | 4 | 9.04E-05 | 9.07E-05 | 4.30E-05 | 1.70E-05 |
| | 5 | 8.72E-05 | 8.74E-05 | 4.13E-05 | 1.60E-05 |
| | 6 | 8.49E-05 | 8.50E-05 | 3.99E-05 | 1.53E-05 |
| | 7 | 8.30E-05 | 8.31E-05 | 3.87E-05 | 1.48E-05 |
| | 8 | 8.14E-05 | 8.14E-05 | 3.77E-05 | 1.43E-05 |
| | 9 | 7.99E-05 | 7.99E-05 | 3.68E-05 | 1.39E-05 |
| | 10 | 7.85E-05 | 7.84E-05 | 3.59E-05 | 1.35E-05 |
| | 20 | 6.82E-05 | 6.80E-05 | 3.07E-05 | 1.14E-05 |
| | 30 | 6.15E-05 | 6.15E-05 | 2.84E-05 | 1.07E-05 |

Table D.8 Count Rate per Bq calculated for the Female phantom contaminated with Co-60

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 2.63E-04 | 6.44E-05 | 7.69E-06 |
| | 1 | 1.29E-04 | 6.30E-05 | 2.09E-05 |
| | 2 | 1.08E-04 | 6.09E-05 | 2.04E-05 |
| | 3 | 9.77E-05 | 5.76E-05 | 1.85E-05 |
| | 4 | 9.24E-05 | 5.49E-05 | 1.71E-05 |
| | 5 | 8.92E-05 | 5.27E-05 | 1.61E-05 |
| | 6 | 8.68E-05 | 5.09E-05 | 1.54E-05 |
| | 7 | 8.48E-05 | 4.93E-05 | 1.48E-05 |
| | 8 | 8.30E-05 | 4.79E-05 | 1.44E-05 |
| | 9 | 8.14E-05 | 4.67E-05 | 1.39E-05 |
| | 10 | 7.99E-05 | 4.56E-05 | 1.36E-05 |
| | 20 | 6.93E-05 | 3.89E-05 | 1.15E-05 |
| | 30 | 6.27E-05 | 3.61E-05 | 1.08E-05 |

Table D.9 Count Rate per Bq calculated for the Adipose Male Phantom contaminated with Co-60

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 1.92E-04 | 4.73E-05 | 3.98E-06 |
| | 1 | 9.29E-05 | 5.11E-05 | 1.81E-05 |
| | 2 | 7.81E-05 | 5.11E-05 | 1.85E-05 |
| | 3 | 7.11E-05 | 4.89E-05 | 1.71E-05 |
| | 4 | 6.73E-05 | 4.68E-05 | 1.59E-05 |
| | 5 | 6.50E-05 | 4.50E-05 | 1.51E-05 |
| | 6 | 6.32E-05 | 4.34E-05 | 1.44E-05 |
| | 7 | 6.18E-05 | 4.20E-05 | 1.39E-05 |
| | 8 | 6.05E-05 | 4.08E-05 | 1.34E-05 |
| | 9 | 5.93E-05 | 3.97E-05 | 1.30E-05 |
| | 10 | 5.83E-05 | 3.87E-05 | 1.27E-05 |
| | 20 | 5.05E-05 | 3.30E-05 | 1.07E-05 |
| | 30 | 4.57E-05 | 3.07E-05 | 1.01E-05 |

Table D.10 Count rate per Bq calculated for the Adipose Female phantom contaminated with Co-60

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 1.98E-04 | 5.08E-05 | 5.14E-06 |
| | 1 | 9.92E-05 | 5.24E-05 | 2.23E-05 |
| | 2 | 8.39E-05 | 5.18E-05 | 2.37E-05 |
| | 3 | 7.64E-05 | 4.94E-05 | 2.25E-05 |
| | 4 | 7.23E-05 | 4.72E-05 | 2.13E-05 |
| | 5 | 6.97E-05 | 4.54E-05 | 2.02E-05 |
| | 6 | 6.78E-05 | 4.38E-05 | 1.94E-05 |
| | 7 | 6.62E-05 | 4.24E-05 | 1.87E-05 |
| | 8 | 6.48E-05 | 4.12E-05 | 1.81E-05 |
| | 9 | 6.36E-05 | 4.01E-05 | 1.75E-05 |
| | 10 | 6.24E-05 | 3.92E-05 | 1.71E-05 |
| | 20 | 5.40E-05 | 3.34E-05 | 1.44E-05 |
| | 30 | 4.90E-05 | 3.10E-05 | 1.36E-05 |

Table D.11 Count rate per Bq calculated for the Post-Menopausal Adipose Female phantom contaminated with Co-60

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 2.03E-04 | 5.33E-05 | 4.94E-06 |
| | 1 | 9.89E-05 | 5.60E-05 | 1.59E-05 |
| | 2 | 8.29E-05 | 5.58E-05 | 1.58E-05 |
| | 3 | 7.52E-05 | 5.34E-05 | 1.45E-05 |
| | 4 | 7.11E-05 | 5.11E-05 | 1.34E-05 |
| | 5 | 6.86E-05 | 4.91E-05 | 1.27E-05 |
| | 6 | 6.68E-05 | 4.74E-05 | 1.21E-05 |
| | 7 | 6.52E-05 | 4.59E-05 | 1.17E-05 |
| | 8 | 6.39E-05 | 4.45E-05 | 1.13E-05 |
| | 9 | 6.26E-05 | 4.34E-05 | 1.09E-05 |
| | 10 | 6.15E-05 | 4.23E-05 | 1.07E-05 |
| | 20 | 5.33E-05 | 3.60E-05 | 9.01E-06 |
| | 30 | 4.82E-05 | 3.35E-05 | 8.47E-06 |

Table D.12 Count rate per Bq calculated for the Child phantom contaminated with Co-60

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 3.36E-04 | 6.67E-05 | 1.91E-05 |
| | 1 | 1.65E-04 | 7.32E-05 | 3.00E-05 |
| | 2 | 1.38E-04 | 6.96E-05 | 2.75E-05 |
| | 3 | 1.25E-04 | 6.53E-05 | 2.44E-05 |
| | 4 | 1.18E-04 | 6.19E-05 | 2.24E-05 |
| | 5 | 1.14E-04 | 5.93E-05 | 2.11E-05 |
| | 6 | 1.11E-04 | 5.72E-05 | 2.02E-05 |
| | 7 | 1.08E-04 | 5.54E-05 | 1.95E-05 |
| | 8 | 1.06E-04 | 5.38E-05 | 1.89E-05 |
| | 9 | 1.04E-04 | 5.23E-05 | 1.84E-05 |
| | 10 | 1.02E-04 | 5.11E-05 | 1.79E-05 |
| | 20 | 8.85E-05 | 4.35E-05 | 1.53E-05 |
| | 30 | 8.01E-05 | 4.05E-05 | 1.42E-05 |

Table D.13 Count rate per Bq calculated for the Male phantom contaminated with Am-241

| | | Back Right Lung | Front Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | Cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 7.16E-05 | 6.84E-05 | 4.75E-07 | 0.00E+00 |
| | 1 | 3.19E-05 | 2.59E-05 | 1.45E-06 | 6.48E-07 |
| | 2 | 2.65E-05 | 2.04E-05 | 1.02E-06 | 4.42E-07 |
| | 3 | 2.46E-05 | 1.82E-05 | 8.57E-07 | 3.35E-07 |
| | 4 | 2.38E-05 | 1.73E-05 | 8.00E-07 | 2.91E-07 |
| | 5 | 2.35E-05 | 1.68E-05 | 7.81E-07 | 2.75E-07 |
| | 6 | 2.34E-05 | 1.66E-05 | 7.77E-07 | 2.70E-07 |
| | 7 | 2.33E-05 | 1.63E-05 | 7.79E-07 | 2.70E-07 |
| | 8 | 2.32E-05 | 1.61E-05 | 7.83E-07 | 2.72E-07 |
| | 9 | 2.31E-05 | 1.59E-05 | 7.87E-07 | 2.74E-07 |
| | 10 | 2.31E-05 | 1.58E-05 | 7.92E-07 | 2.76E-07 |
| | 20 | 2.26E-05 | 1.42E-05 | 8.33E-07 | 2.97E-07 |
| | 30 | 2.23E-05 | 1.29E-05 | 8.62E-07 | 3.12E-07 |

Table D.14 Count rate per Bq calculated for the Female phantom contaminated with Am-241

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 6.49E-05 | 5.64E-07 | 0.00E+00 |
| | 1 | 3.27E-05 | 1.53E-06 | 6.99E-07 |
| | 2 | 2.83E-05 | 1.08E-06 | 4.75E-07 |
| | 3 | 2.67E-05 | 9.09E-07 | 3.54E-07 |
| | 4 | 2.62E-05 | 8.49E-07 | 3.02E-07 |
| | 5 | 2.60E-05 | 8.29E-07 | 2.84E-07 |
| | 6 | 2.60E-05 | 8.24E-07 | 2.78E-07 |
| | 7 | 2.60E-05 | 8.26E-07 | 2.78E-07 |
| | 8 | 2.60E-05 | 8.30E-07 | 2.79E-07 |
| | 9 | 2.60E-05 | 8.34E-07 | 2.81E-07 |
| | 10 | 2.61E-05 | 8.39E-07 | 2.84E-07 |
| | 20 | 2.66E-05 | 8.79E-07 | 3.05E-07 |
| | 30 | 2.72E-05 | 9.08E-07 | 3.20E-07 |

Table D.15 Count rate per Bq calculated for the Adipose Male phantom contaminated with Am-241

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 4.15E-05 | 4.52E-07 | 4.52E-07 |
| | 1 | 2.10E-05 | 1.38E-06 | 1.38E-06 |
| | 2 | 1.82E-05 | 9.69E-07 | 9.69E-07 |
| | 3 | 1.72E-05 | 8.17E-07 | 8.17E-07 |
| | 4 | 1.68E-05 | 7.62E-07 | 7.62E-07 |
| | 5 | 1.67E-05 | 7.45E-07 | 7.45E-07 |
| | 6 | 1.67E-05 | 7.41E-07 | 7.41E-07 |
| | 7 | 1.67E-05 | 7.43E-07 | 7.43E-07 |
| | 8 | 1.67E-05 | 7.46E-07 | 7.46E-07 |
| | 9 | 1.68E-05 | 7.50E-07 | 7.50E-07 |
| | 10 | 1.68E-05 | 7.55E-07 | 7.55E-07 |
| | 20 | 1.71E-05 | 7.94E-07 | 7.94E-07 |
| | 30 | 1.76E-05 | 8.21E-07 | 8.21E-07 |

Table D.16 Count rate per Bq calculated for the Adipose Female phantom contaminated with Am-241

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 5.13E-05 | 5.26E-07 | 1.33E-09 |
| | 1 | 2.55E-05 | 1.43E-06 | 1.17E-06 |
| | 2 | 2.19E-05 | 1.00E-06 | 8.01E-07 |
| | 3 | 2.07E-05 | 8.48E-07 | 6.39E-07 |
| | 4 | 2.02E-05 | 7.92E-07 | 5.76E-07 |
| | 5 | 2.01E-05 | 7.73E-07 | 5.54E-07 |
| | 6 | 2.00E-05 | 7.69E-07 | 5.49E-07 |
| | 7 | 2.00E-05 | 7.70E-07 | 5.51E-07 |
| | 8 | 2.01E-05 | 7.74E-07 | 5.55E-07 |
| | 9 | 2.01E-05 | 7.78E-07 | 5.59E-07 |
| | 10 | 2.01E-05 | 7.82E-07 | 5.64E-07 |
| | 20 | 2.04E-05 | 8.20E-07 | 6.06E-07 |
| | 30 | 2.08E-05 | 8.47E-07 | 6.38E-07 |

Table D.17 Count rate per Bq calculated for the Post-Menopausal Adipose Female phantom contaminated with Am-241

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 4.49E-05 | 5.74E-07 | 0.00E+00 |
| | 1 | 2.29E-05 | 1.51E-06 | 5.28E-07 |
| | 2 | 1.98E-05 | 1.06E-06 | 3.59E-07 |
| | 3 | 1.88E-05 | 8.98E-07 | 2.66E-07 |
| | 4 | 1.84E-05 | 8.38E-07 | 2.27E-07 |
| | 5 | 1.83E-05 | 8.18E-07 | 2.13E-07 |
| | 6 | 1.83E-05 | 8.14E-07 | 2.09E-07 |
| | 7 | 1.83E-05 | 8.16E-07 | 2.09E-07 |
| | 8 | 1.83E-05 | 8.19E-07 | 2.10E-07 |
| | 9 | 1.84E-05 | 8.24E-07 | 2.11E-07 |
| | 10 | 1.84E-05 | 8.28E-07 | 2.13E-07 |
| | 20 | 1.88E-05 | 8.68E-07 | 2.29E-07 |
| | 30 | 1.93E-05 | 8.95E-07 | 2.40E-07 |

Table D.18 Count rate per Bq calculated for the Child phantom contaminated with Am-241

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 1.11E-04 | 1.87E-06 | 0.00E+00 |
| | 1 | 5.02E-05 | 3.39E-06 | 1.15E-06 |
| | 2 | 4.18E-05 | 2.41E-06 | 7.54E-07 |
| | 3 | 3.87E-05 | 2.04E-06 | 5.17E-07 |
| | 4 | 3.75E-05 | 1.91E-06 | 4.15E-07 |
| | 5 | 3.70E-05 | 1.86E-06 | 3.76E-07 |
| | 6 | 3.67E-05 | 1.85E-06 | 3.63E-07 |
| | 7 | 3.66E-05 | 1.85E-06 | 3.60E-07 |
| | 8 | 3.65E-05 | 1.86E-06 | 3.61E-07 |
| | 9 | 3.64E-05 | 1.87E-06 | 3.63E-07 |
| | 10 | 3.63E-05 | 1.87E-06 | 3.66E-07 |
| | 20 | 3.57E-05 | 1.94E-06 | 3.92E-07 |
| | 30 | 3.53E-05 | 1.98E-06 | 4.12E-07 |

Table D.19 Count rate per Bq calculated for the Male phantom contaminated with I-131

| | | Back Right Lung | Front Right Lung | Neck | Thigh |
|-------------------------|----|-----------------|------------------|------------|------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 2.86E-04 | 2.75E-04 | 2.42E-06 | 1.90E-07 |
| | 1 | 3.35E-05 | 3.28E-05 | 8.61E-05 | 1.02E-06 |
| | 2 | 1.11E-05 | 1.16E-05 | 8.14E-05 | 6.12E-07 |
| | 3 | 4.69E-06 | 5.36E-06 | 7.48E-05 | 8.07E-07 |
| | 4 | 2.71E-06 | 3.41E-06 | 6.86E-05 | 9.83E-07 |
| | 5 | 2.15E-06 | 2.82E-06 | 6.28E-05 | 1.11E-06 |
| | 6 | 2.02E-06 | 2.65E-06 | 5.76E-05 | 1.20E-06 |
| | 7 | 2.01E-06 | 2.60E-06 | 5.27E-05 | 1.26E-06 |
| | 8 | 2.02E-06 | 2.57E-06 | 4.83E-05 | 1.29E-06 |
| | 9 | 2.02E-06 | 2.52E-06 | 4.42E-05 | 1.29E-06 |
| | 10 | 1.99E-06 | 2.46E-06 | 4.05E-05 | 1.28E-06 |
| | 20 | 1.26E-06 | 1.46E-06 | 1.65E-05 | 8.20E-07 |
| | 30 | 6.10E-07 | 6.91E-07 | 6.67E-06 | 3.97E-07 |

Table D.20 Count rate per Bq calculated for the Female phantom contaminated with I-131

| | | Back Right Lung | Neck | Thigh |
|-------------------------|----|-----------------|------------|------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 2.66E-04 | 2.38E-06 | 2.51E-07 |
| | 1 | 3.17E-05 | 7.16E-05 | 9.49E-07 |
| | 2 | 1.09E-05 | 6.75E-05 | 5.65E-07 |
| | 3 | 4.99E-06 | 6.21E-05 | 7.42E-07 |
| | 4 | 3.26E-06 | 5.71E-05 | 9.03E-07 |
| | 5 | 2.80E-06 | 5.24E-05 | 1.02E-06 |
| | 6 | 2.73E-06 | 4.81E-05 | 1.10E-06 |
| | 7 | 2.75E-06 | 4.41E-05 | 1.15E-06 |
| | 8 | 2.77E-06 | 4.05E-05 | 1.18E-06 |
| | 9 | 2.77E-06 | 3.71E-05 | 1.19E-06 |
| | 10 | 2.73E-06 | 3.40E-05 | 1.18E-06 |
| | 20 | 1.72E-06 | 1.40E-05 | 7.53E-07 |
| | 30 | 8.28E-07 | 5.69E-06 | 3.64E-07 |

Table D.21 Count rate per Bq calculated for the Adipose Male phantom contaminated with I-131

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 1.83E-04 | 1.77E-06 | 1.07E-07 |
| | 1 | 2.18E-05 | 7.53E-05 | 9.03E-07 |
| | 2 | 7.44E-06 | 7.13E-05 | 5.42E-07 |
| | 3 | 3.39E-06 | 6.55E-05 | 7.19E-07 |
| | 4 | 2.18E-06 | 6.01E-05 | 8.77E-07 |
| | 5 | 1.86E-06 | 5.51E-05 | 9.94E-07 |
| | 6 | 1.81E-06 | 5.05E-05 | 1.07E-06 |
| | 7 | 1.82E-06 | 4.63E-05 | 1.12E-06 |
| | 8 | 1.83E-06 | 4.24E-05 | 1.15E-06 |
| | 9 | 1.82E-06 | 3.88E-05 | 1.16E-06 |
| | 10 | 1.80E-06 | 3.55E-05 | 1.15E-06 |
| | 20 | 1.13E-06 | 1.45E-05 | 7.34E-07 |
| | 30 | 5.45E-07 | 5.87E-06 | 3.56E-07 |

Table D.22 Count rate per Bq calculated for the Adipose Female phantom contaminated with I-131

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 1.99E-04 | 1.85E-06 | 1.76E-07 |
| | 1 | 2.39E-05 | 6.05E-05 | 1.37E-06 |
| | 2 | 8.20E-06 | 5.71E-05 | 8.45E-07 |
| | 3 | 3.79E-06 | 5.26E-05 | 1.12E-06 |
| | 4 | 2.48E-06 | 4.83E-05 | 1.37E-06 |
| | 5 | 2.13E-06 | 4.44E-05 | 1.55E-06 |
| | 6 | 2.07E-06 | 4.07E-05 | 1.68E-06 |
| | 7 | 2.08E-06 | 3.74E-05 | 1.75E-06 |
| | 8 | 2.09E-06 | 3.43E-05 | 1.79E-06 |
| | 9 | 2.09E-06 | 3.14E-05 | 1.80E-06 |
| | 10 | 2.06E-06 | 2.88E-05 | 1.79E-06 |
| | 20 | 1.29E-06 | 1.19E-05 | 1.14E-06 |
| | 30 | 6.20E-07 | 4.82E-06 | 5.54E-07 |

Table D.23 Count rate per Bq calculated for the Post-Menopausal Adipose Female phantom contaminated with I-131

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 1.94E-04 | 2.01E-06 | 1.63E-07 |
| | 1 | 2.32E-05 | 6.84E-05 | 6.89E-07 |
| | 2 | 7.94E-06 | 6.46E-05 | 4.05E-07 |
| | 3 | 3.64E-06 | 5.94E-05 | 5.29E-07 |
| | 4 | 2.35E-06 | 5.46E-05 | 6.42E-07 |
| | 5 | 2.00E-06 | 5.01E-05 | 7.25E-07 |
| | 6 | 1.93E-06 | 4.60E-05 | 7.82E-07 |
| | 7 | 1.93E-06 | 4.22E-05 | 8.18E-07 |
| | 8 | 1.94E-06 | 3.87E-05 | 8.37E-07 |
| | 9 | 1.93E-06 | 3.55E-05 | 8.41E-07 |
| | 10 | 1.90E-06 | 3.26E-05 | 8.34E-07 |
| | 20 | 1.18E-06 | 1.34E-05 | 5.33E-07 |
| | 30 | 5.67E-07 | 5.46E-06 | 2.58E-07 |

Table D.24 Count rate per Bq for the Child phantom contaminated with I-131

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 3.65E-04 | 2.22E-06 | 8.02E-07 |
| | 1 | 4.48E-05 | 5.43E-05 | 1.20E-06 |
| | 2 | 1.54E-05 | 5.06E-05 | 7.16E-07 |
| | 3 | 7.28E-06 | 4.71E-05 | 8.96E-07 |
| | 4 | 4.88E-06 | 4.38E-05 | 1.07E-06 |
| | 5 | 4.24E-06 | 4.06E-05 | 1.19E-06 |
| | 6 | 4.13E-06 | 3.77E-05 | 1.28E-06 |
| | 7 | 4.14E-06 | 3.49E-05 | 1.33E-06 |
| | 8 | 4.15E-06 | 3.23E-05 | 1.36E-06 |
| | 9 | 4.13E-06 | 2.98E-05 | 1.37E-06 |
| | 10 | 4.06E-06 | 2.75E-05 | 1.35E-06 |
| | 20 | 2.51E-06 | 1.20E-05 | 8.57E-07 |
| | 30 | 1.21E-06 | 4.98E-06 | 4.14E-07 |

Table D.25 Count Rate per Bq for the Male Phantom Contaminated with I-192

| | | Back Right Lung | Front Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 3.45E-04 | 3.31E-04 | 3.07E-06 | 1.73E-07 |
| | 1 | 1.35E-04 | 1.30E-04 | 1.76E-05 | 9.62E-06 |
| | 2 | 1.08E-04 | 1.04E-04 | 1.82E-05 | 9.45E-06 |
| | 3 | 9.71E-05 | 9.38E-05 | 1.80E-05 | 8.88E-06 |
| | 4 | 9.19E-05 | 8.88E-05 | 1.78E-05 | 8.58E-06 |
| | 5 | 8.89E-05 | 8.59E-05 | 1.77E-05 | 8.43E-06 |
| | 6 | 8.67E-05 | 8.38E-05 | 1.77E-05 | 8.36E-06 |
| | 7 | 8.48E-05 | 8.20E-05 | 1.76E-05 | 8.31E-06 |
| | 8 | 8.31E-05 | 8.04E-05 | 1.75E-05 | 8.28E-06 |
| | 9 | 8.15E-05 | 7.88E-05 | 1.74E-05 | 8.25E-06 |
| | 10 | 7.99E-05 | 7.73E-05 | 1.74E-05 | 8.22E-06 |
| | 20 | 6.64E-05 | 6.44E-05 | 1.68E-05 | 8.01E-06 |
| | 30 | 5.59E-05 | 5.43E-05 | 1.63E-05 | 7.77E-06 |

Table D.26 Count rate per Bq for the Female phantom contaminated with I-192

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 3.21E-04 | 3.14E-06 | 2.19E-07 |
| | 1 | 1.30E-04 | 1.84E-05 | 8.94E-06 |
| | 2 | 1.05E-04 | 1.90E-05 | 8.73E-06 |
| | 3 | 9.47E-05 | 1.88E-05 | 8.16E-06 |
| | 4 | 8.98E-05 | 1.87E-05 | 7.86E-06 |
| | 5 | 8.70E-05 | 1.85E-05 | 7.72E-06 |
| | 6 | 8.50E-05 | 1.85E-05 | 7.65E-06 |
| | 7 | 8.32E-05 | 1.84E-05 | 7.61E-06 |
| | 8 | 8.16E-05 | 1.83E-05 | 7.58E-06 |
| | 9 | 8.01E-05 | 1.82E-05 | 7.55E-06 |
| | 10 | 7.86E-05 | 1.82E-05 | 7.52E-06 |
| | 20 | 6.59E-05 | 1.76E-05 | 7.32E-06 |
| | 30 | 5.60E-05 | 1.70E-05 | 7.10E-06 |

Table D.27 Count rate per Bq for the Adipose Male phantom contaminated with I-192

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 2.23E-04 | 2.41E-06 | 7.28E-08 |
| | 1 | 8.97E-05 | 1.60E-05 | 8.57E-06 |
| | 2 | 7.24E-05 | 1.65E-05 | 8.44E-06 |
| | 3 | 6.53E-05 | 1.64E-05 | 7.94E-06 |
| | 4 | 6.19E-05 | 1.63E-05 | 7.67E-06 |
| | 5 | 6.00E-05 | 1.62E-05 | 7.55E-06 |
| | 6 | 5.86E-05 | 1.61E-05 | 7.48E-06 |
| | 7 | 5.73E-05 | 1.61E-05 | 7.44E-06 |
| | 8 | 5.62E-05 | 1.60E-05 | 7.41E-06 |
| | 9 | 5.52E-05 | 1.59E-05 | 7.38E-06 |
| | 10 | 5.42E-05 | 1.59E-05 | 7.36E-06 |
| | 20 | 4.54E-05 | 1.54E-05 | 7.17E-06 |
| | 30 | 3.85E-05 | 1.49E-05 | 6.95E-06 |

Table D.28 Count rate per Bq for the Adipose Female phantom contaminated with I-192

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 2.45E-04 | 2.37E-06 | 1.69E-07 |
| | 1 | 9.91E-05 | 1.56E-05 | 1.24E-05 |
| | 2 | 8.01E-05 | 1.61E-05 | 1.27E-05 |
| | 3 | 7.23E-05 | 1.60E-05 | 1.23E-05 |
| | 4 | 6.86E-05 | 1.59E-05 | 1.20E-05 |
| | 5 | 6.65E-05 | 1.58E-05 | 1.19E-05 |
| | 6 | 6.49E-05 | 1.57E-05 | 1.18E-05 |
| | 7 | 6.36E-05 | 1.57E-05 | 1.18E-05 |
| | 8 | 6.23E-05 | 1.56E-05 | 1.17E-05 |
| | 9 | 6.12E-05 | 1.55E-05 | 1.17E-05 |
| | 10 | 6.00E-05 | 1.55E-05 | 1.17E-05 |
| | 20 | 5.04E-05 | 1.50E-05 | 1.14E-05 |
| | 30 | 4.28E-05 | 1.45E-05 | 1.10E-05 |

Table D.29 Count rate per Bq for the Post-Menopausal Adipose Female phantom contaminated with I-192

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 2.40E-04 | 2.66E-06 | 7.67E-08 |
| | 1 | 9.63E-05 | 1.75E-05 | 6.71E-06 |
| | 2 | 7.77E-05 | 1.82E-05 | 6.43E-06 |
| | 3 | 7.00E-05 | 1.80E-05 | 5.90E-06 |
| | 4 | 6.64E-05 | 1.79E-05 | 5.63E-06 |
| | 5 | 6.43E-05 | 1.78E-05 | 5.51E-06 |
| | 6 | 6.28E-05 | 1.77E-05 | 5.45E-06 |
| | 7 | 6.14E-05 | 1.76E-05 | 5.42E-06 |
| | 8 | 6.02E-05 | 1.76E-05 | 5.39E-06 |
| | 9 | 5.91E-05 | 1.75E-05 | 5.37E-06 |
| | 10 | 5.80E-05 | 1.74E-05 | 5.36E-06 |
| | 20 | 4.86E-05 | 1.69E-05 | 5.21E-06 |
| | 30 | 4.12E-05 | 1.64E-05 | 5.06E-06 |

Table D.30 Count rate per Bq for the Child phantom contaminated with I-192

| | | Back Right Lung | Neck | Thigh |
|--------------------------------|----|------------------------|-------------------|-------------------|
| | | cpm per Bq | cpm per Bq | cpm per Bq |
| Days following exposure | 0 | 4.41E-04 | 4.31E-06 | 5.75E-07 |
| | 1 | 1.80E-04 | 3.12E-05 | 1.09E-05 |
| | 2 | 1.45E-04 | 3.23E-05 | 1.04E-05 |
| | 3 | 1.31E-04 | 3.20E-05 | 9.55E-06 |
| | 4 | 1.25E-04 | 3.17E-05 | 9.12E-06 |
| | 5 | 1.21E-04 | 3.16E-05 | 8.93E-06 |
| | 6 | 1.18E-04 | 3.14E-05 | 8.83E-06 |
| | 7 | 1.16E-04 | 3.13E-05 | 8.77E-06 |
| | 8 | 1.13E-04 | 3.12E-05 | 8.73E-06 |
| | 9 | 1.11E-04 | 3.10E-05 | 8.70E-06 |
| | 10 | 1.09E-04 | 3.09E-05 | 8.67E-06 |
| | 20 | 9.19E-05 | 3.00E-05 | 8.43E-06 |
| | 30 | 7.83E-05 | 2.90E-05 | 8.16E-06 |

REFERENCES

1. Anigstein, R., Erdman, M., King, S., Mauro, J., Miller, K., and Olsher, R. (2007). Use of Radiation Detection, Measuring, and Imaging Instruments to Assess Internal Contamination from Inhaled Radionuclides, Part I and Part II. S. Cohen & Associates, Contract Number 200-2002-00367
2. Argonne National Laboratory, (2002) Radiological Dispersal Device: Human Health Fact Sheet
3. Attix, F.H. (1986) Introduction to Radiological Physics and Radiation Dosimetry. (John Wiley and Sons, New York)
4. Capintec, Inc. Captus 3000 Thyroid Uptake System User's Manual. (2007)
5. Capintec, Inc. Website: www.capintec.com (Last accessed March, 2008)
6. DOE/NRC Interagency Working Group on Radiological Dispersal Devices. Radiological Dispersal Devices: An Initial Study To Identify Radioactive Materials of Greatest Concern And Approaches To Their Tracking, Tagging, And Disposition. Report to the Nuclear Regulatory Commission and the Secretary of Energy, May 2003.
7. Eckerman, K.F., Cristy, M., Ryman, J.C., The ORNL Mathematical Phantom Series, Oak Ridge National Laboratory, <http://homer.hsr.gov/VLab/VLabPhan.html>. (1996)
8. Eckerman, K.F., Sjoreen, A.L., Radiological Toolbox. ORNL/TM-2004/27R1.
9. Eckerman, K.F., et al, Dose and Risk Calculation Software. ORML/TM-2001/190.
10. International Commission on Radiological Protection (ICRP) (1975). Report of the Task Group on Reference Man. ICRP Publication 23.
11. International Commission on Radiological Protection (ICRP) (1977). Recommendations of the ICRP. ICRP Publication 26. Annals of the ICRP, Volume 3, No. 1-4.
12. International Commission on Radiological Protection (ICRP). (1979). Limits for Intakes by Workers. ICRP Publication 30, Part 1, Pergamon Press, Oxford.
13. International Commission on Radiological Protection (ICRP). (1983). Radionuclide Transformations Energy and Intensity of Emission. ICRP Publication 38, Pergamon Press, Oxford.

14. International Commission on Radiological Protection (ICRP). 1989. Age-Dependent Doses to Members of the Public from Intake of Radionuclides, Part 1. ICRP Publication 56, Pergamon Press, Oxford.
15. International Commission on Radiological Protection (ICRP) (1991). Recommendations of the ICRP. ICRP Publication 60. Annals of the ICRP, Volume 21, No 1-3.
16. International Commission on Radiological Protection (ICRP). (1993). Age-Dependent Doses to Members of the Public from Intake of Radionuclides, Part 2. ICRP Publication 67, Pergamon Press, Oxford.
17. International Commission on Radiological Protection (ICRP). (1994a). Human Respiratory Tract Model for Radiological Protection. ICRP Publication 66, Pergamon Press, Oxford.
18. International Commission on Radiological Protection (ICRP). (1994b). Dose Coefficients for Intakes of Radionuclides by Workers. ICRP Publication 68, Pergamon Press, Oxford.
19. International Commission on Radiological Protection (ICRP). (1995a). Age-Dependent Doses to Members of the Public from Intake of Radionuclides, Part 3. ICRP Publication 69, Pergamon Press, Oxford.
20. International Commission on Radiological Protection (ICRP). (1995b). Age-Dependent Doses to Members of the Public from Intake of Radionuclides, Part 4. ICRP Publication 71, Pergamon Press, Oxford.
21. International Commission on Radiological Protection (ICRP) (1996) 91 Age-dependent dose to members of the public from intake of radionuclides: Part 5 compilation of ingestion and inhalation dose coefficients. Annals of the ICRP, Volume 26, Issue 1
22. International Commission on Radiation Units and Measurements (ICRU). (1992). Phantoms and Computational Models in Therapy, Diagnosis, and Protection. ICRU Report 48. Bethesda, MD.
23. Knoll, G.F. (2000). Radiation Detection and Measurement, Third Edition. (John Wiley and Sons, New York).
24. Lorio, R. A. Feasibility of Determining Radioactivity in Lungs Using A Thyroid Uptake Counter: A Thesis Presented to the Faculty. Georgia Institute of Technology (2005).
25. Lugar, R.G. (2005) The Lugar Survey on Proliferation Threats and Responses. <http://lugar.senate.gov/reports/NPSurvey.pdf>. (Accessed February, 2008)
26. AISI 1000: Material composition of mild grain controlled steel. www.Matls.com (Accessed June, 2007).

27. Marcus, C.S., Siegel, J.A. Medical Management of Internally Radiocontaminated Patients. (2006)
28. Mathematica Version 6. Wolfram Research, Inc., 2007.
29. MCNP A General Monte Carlo N-Particle Transport Code Version 5, Volumes I, II, and III: User's Guide. LA-CP-03-0245. LANL x-5 Monte Carlo Team, April 2003.
30. National Council on Radiation Protection (NCRP) (1980). Management of Persons Accidentally Contaminated with Radionuclides, NCRP Report 65. Washington, DC.
31. NIOSH Dose Reconstruction Project. ORAUT-0TIB-0002, ORAUT-TKBS-0010-5, ORAUT-TKBS-0049, ORAUT-TKBS-003605.
32. NIST Standard Reference Materials. <http://nist.gov/srm>. (Accessed June, 2007)
33. Oliveira, C., Lourenco, M., Dantas, B., Lucena, E., Design and Operation of a Whole-body Monitoring System for the Goiania Radiation Accident. Health Physics. 60(1):51-55, January 1991.
34. Personal Communication with Dr. Armin Ansari. February 18, 2008.
35. Saint-Gobain Crystals NaI(Tl) Scintillation Material Properties Sheet. (2005)
36. Sandia National Laboratories. An Initial Study to Identify Materials of Greatest Concern for Use in a Radiological Dispersal Device. (2002)
37. Simpkins, R. Hertel, N. (2003) Neutron Organ Dose and the Influence of Adipose Tissue. American Nuclear Society, Radiation Protection and Shielding Division 12th Biennial Topical Meeting presentation
38. Smith, J., Ansari, A., Harper, F. (2005) Hospital Management of Mass Radiological Casualties: Reassessing Exposures from Contaminated Victims of an Exploded Radiological Dispersal Device. Health Physics. 89(5):513-520.
39. Sohler, A., Hardeman, F. (2006) Radiological Dispersion Devices: are we prepared? Journal of Environmental Radioactivity 85 pp 171-181.
40. Strom, D. (1998) False Alarms, True Alarms, and Statistics: Correct Usage of Decision Level and Minimum Detectable Amount. Health Physics Society, Continuing Education Lecture, Minneapolis, Minnesota, July 15, 1998.
41. Turner, J.E. (1995). Atoms, Radiation, and Radiation Protection, Second Edition. (John Wiley and Sons, New York).

42. Ueda, Normal Volume of the Thyroid Gland in Children. (1990) Journal of Clinical Ultrasound, Volume 18, Issue 6, pg 455-462.
43. Wang, Z, Hertel N. (2005) Determination of dosimetric characteristics of OptiSeed a plastic brachytherapy Pd-103 source. Applied Radiation and Isotopes, 63 (2005) pp 311-321.
44. White Rock Science (2004). Bodybuilder,
<http://www.whiterockscience.com/bodybuilder/bodybuilder.html>.
45. X-5 Monte Carlo Team. (2003). MCNP – A General Monte Carlo N-Particle Transport Code, Version 5. LA-UR-03-1987.
46. X-5 Monte Carlo Team. (2003). VisEd Version 19L, November 2005.